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ABSTRACT 
Approximately 50% of all prunary open-angle glaucoma (POAG) is familial. 
Investigation of clinical risk factors associated with familial POAG may help to identify 
phenotypic subtypes of the disease, each with different pathophysiologic mechanisms 
that may be modified by intervention and disease-prevention strategies. 
In a cross-sectional retrospective study of 2940 'glaucoma' patients over 10 years of age 
in Tasmania, the prevalence of nine potential clinical risk factors (hypertension, diabetes 
mellitus, migraine headache, corticosteroids use, smoking, atherosclerosis, cold 
extremities, blood transfusion, thyroid disorders) were compared using multi-stepped 
regression analysis between 1014 patients with familial glaucoma and 688 patients with 
sporadic or non-familial glaucoma classified by Glaucoma Inheritance Study in Tasmania 
(GIST) scores (intraocular pressure, optic disc and visual field changes) and genealogic 
data. 59.6% of all subjects with POAG have a positive family history of POAG. 
There is no significant difference in the distribution of gender between the familial and 
sporadic POAG groups (OR 1.053; 95%CI 0.819-1.353). 
No risk factor examined is significantly different in the familial glaucoma group in 
comparison to the sporadic glaucoma group, after adjusting for confounding effects of 
age and gender, GIST scores, degree of relatives or other potential clinical risk factors. 
XXl 
The distribution of GIST scores in the familial glaucoma group is skewed towards the 
higher spectrum and is significantly different from that of the sporadic glaucoma group 
(p<0.001), suggesting the likelihood of an earlier onset and/or a greater severity of 
glau~oma in the familial group. 
XXll 
CHAPTER I 
INTRODUCTION 
"It is amazing how such a small window can open out to such a large world. " 
(William Shakespeare) 
I.I GLAUCOMA 
After cataract, glaucoma is the second leading cause of blindness in the world, with an 
estimated worldwide prevalence of approximately 70 million people, half of whom have open-
angle glaucoma (Flanagan 1993; Sh,ields 1982; Spaeth 1998; Quigley 1996). Infrequent in 
people below the age of 50, glaucoma affects up to 10% of the population over the age of 80 
(Wensor 1998). 
Currently, glaucoma is not considered to be a disease per se but rather a slowly progressive, 
ins1chous optic neuropathy characterised by a specific pattern of optic nerve damage, which 
includes optic disc excavation ('cupping'). The subsequent visual field loss may represent the 
endpoint of a final common pathway resulting from a number of different aetiological agents 
affecting the eye (Vaughan 1992; Berson 1993; Drance 1988; Horton 1998). 
At present, there is no known treatment to restore vision lost from glaucoma. However, 
early detection of the disease and administration of appropriate treatment can prevent 
blindness (Hoskins and Kass 1989). Visual impaitment resulting from glaucoma imposes a 
significant physical, emotional, social and economic burden on an mdividual and has a 
negative impact on quality of life (Weih 2000). 
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Approximately 50% of all glaucoma is familial (Mitchell 1996; McNaught 2000). Many 
stuches have examined the relationslnp between total (familial and sporadic) primary open-
angle glaucoma (POAG) and various climcal risk factors, such as hypertension, diabetes 
mellitus and migraine, but no study to date has yet compared the relationship between these 
risk factors and the familial or sporadic glaucoma subgroups. The aim of this thesis is to 
mvestlgate clinical risk factors associated with familial POAG; these risk factors may be used 
to identify phenotypic subtypes of the disease, each with potentially different 
pathophysiologic mechanisms that may be mochfied by intervention and disease-prevention 
strategies. 
I.II CLASSIFICATION 
In terms of pathogenesis and clinical expression, glaucoma is a highly heterogeneous group of 
eye disorders (Spaeth 1998). It has a few generally accepted and clinically valid subgroups 
(Caprioli 1993), including those based on anterior chamber width, age of onset, intraocular 
pressure (IOP) level and disease progression (Spaeth 1976; Geijssen 1987). 
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As illustrated in Table 1.1, glaucoma can be classified into three broad categories based on 
the cause for poor aqueous outflow: Open-angle, Closed-angle and 
Congenital/Developmental. Congenital glaucoma presents at birth or during the first year of 
life with buphthalmos, and may be associated with an inherited syndrome of ocular anterior 
segment dysgenesis (Craig 1999). Each of these can be further subdivided into primary types 
in which the glaucoma 1s not associated with any other systemic or ocular disorder and 
secondary types resulting from a pre-existing ocular or systemic disease (Duke-Elder 1941). 
Indeed, recognition of the spectrum of manifestations of glaucoma is required for early 
diagnosis and appropriate management of individual cases. 
Table 1.1 A classification system for glaucoma (Vaughan 1992; Alward 1998). 
Types 
Primary 
Secondary 
Open-angle 
POAG 
JOAG 
low-tension glaucoma 
angle recession 
aphakia 
corticosteroid 
pseudoexfoliation 
syndrome 
ghost cells 
haemmorrhage& 
neuovascularisation 
inflammation & uveitis 
phagolyric changes in the 
iris 
pigment 
s ndrome 
dispersion 
Closed-angle 
pupillary block 
plateau iris syndrome 
Aqueous misdirection 
(malignant glaucoma) 
ciliarr body swelling 
ectopic lentis 
epithelial downgrowth 
Fuch's endothelial sy~drome 
iridoschisis 
posterio polymorphos 
corneal dystrophy 
Congenital/ 
Pevelopmental 
Primary 
associated with 
*aniridia 
*Axenfeld-Rieger 
syndrome 
*neurofibromatosis 
*Peter's anomaly 
*Sturge-Weber syndrome 
aphakia 
retinoblastome 
retinopathy of prematurity 
JOAG- Juvenile-onset open-;ngle glaucoma; POAG - Primary open-angle glaucoma. 
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I.Iii PRIMARY OPEN-ANGLE GLAUCOMA (POAG) 
Open-angle glaucoma is the most common type of glaucoma in 'Western' developed 
countries (Flanagan 1993). The .u:idocomeal angle is not narrowed, but the aqueous humour 
that flows through the pupil into the anterior chamber cannot pass through the trabecular 
meshwork into the normal venous drainage system (Figure I.la). This is usually secondary 
to an increased resistance to aqueous flow in Schlemm's canal or in the trabecular meshwork 
(Figure I.lb) (Vaughan 1992; Berson 1993). Most open-angle glaucoma 1s of the primary 
type, but it can also be congemtal or secondary due to other abnormalities such as 
pseudoexfoliation syndrome, neovascularisation, uveitis, an~ pigment dispersion syndrome 
(Alward 1998). 
Vitreous 
Figure I.la. Schematic diagram of the anterior segment of the eye. The conventional 
pathway followed by aqueous humour from the posterior chamber to the anterior 
chamber and outflow pathways are shown by arrows (Bron et al, 1997 pp302). 
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Figure I.lb. Histology and ultrastructure of the trabecular meshwork and Schlemm's 
canal (Forrester et al, 1999 pp21). 
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POAG, also known as chronic simple glaucoma, is generally a bilateral although not 
necessarily symmetrical disease, often with the following characteristics: 
• Adult onset (usually in the sixth decade) 
• IOP greater than 21 mmHg at some point in the course of disease 
• Open anterior chamber angle of normal appearance with visualisation of the full 
extent of trabecular meshwork, scleral spur and ins processes on gonioscopy 
(Vaughan 1992) 
• Glaucomatous optic nerve head damage, such as optic disc enlargement associated 
with disc pallor in the area of cupping, attenuated neural rim with dipping of retinal 
vessels (bean pot cup), cup-disc ratio> 0.5 or significant asymmetry between the two 
eyes (cup-disc ratio difference > 0.2), splinter haemorrhages and atrophy of the 
nerve fibre layer (Hoyt's sign) ( Figure 1.2 ) (Sommer 1991; Vaughan 1992; 
Tuulonen 1993) 
• Visual field loss, such as the characteristic Bjernum scotoma, arcuate sc;otoma and 
nasal step of Roenne (Figures I.3a; I.3b; I.3c) (Vaughan 1992; Kanskl 1999). 
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Figure 1.2. Photographs of glaucomatous optic nerve head damage 
rap111omacurarl 
b~ndle I 
Nasal 
:-..~;_;...--+,..,---1 retina 
i 
i 
Figure l.3a Anatomy of the retinal nerve fibers ( Kanski, 1999 pp194). 
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Figure I.3b Progression of the visual field loss (Kanski, 1999 pp204). 
Left eye Right eye 
Figure I.3c Visual field analysis of an affected glaucoma patient from the study. 
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It must be noted, however, that there is a lack of universal agreement on the definition and 
hence diagnosis of glaucoma (I<::ahn 1980; Wilson 1993). 
Most people who develop POAG notice no symptoms unttl vision is impaired and damage 
is marked, giving it the reputation as the "sneak thief of sight" (Vaughan 1992; Berson 
1993). In developed countries, up to 50%-60% of those affected by glaucoma remain 
undiagnosed (Mitchell 1996; Quigley 1996; Wensor 1998; Weih 2901). As optic nerve fibres 
are damaged by glaucoma, scotomas may begin to develop insidiously over many years, 
initially affecting peripheral nasal vision that is well covered by the field of the fellow eye 
(Vaughan 1992; Berson 1993; Spaeth 1998; Kanski 1999). In the later stages of the disease 
penpheral temporal and central 3-10 degrees of vision are affected (Vaughan 1992; Berson 
1993; Spaeth 1998; Kanskl 1999). 
Approximately 16% of all patients with otherwise characteristic POAG have IOPs 
consistently under 22mmHg and they form a subgroup referred to as "normal-tension" or 
"low-tension" glaucoma (I<::anski, 1999). 
Juverule-onset open-angle glaucoma Q"OAG) is an uncommon subtype, characterised by a 
more severe course and an earlier onset (typically <35 years of age although the cutoff age is 
not consistent between authors) (Kitsos et al. 1995). 
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I.IV PATHOPHYSIOLOGY 
It is generally accepted that increased resistance to aqueous outflow in the drainage channels 
causes elevation of IOP in POAG and that the development of visual field loss is related to 
progressive loss of axons in the optic nerve head. However, speculation abounds as to how 
the two processes are linked. Several mechanisms have been postulated to explain the optic 
nerve head damage, but no single mechanism can adequately explain the great variation in 
susceptibility to damage and the pattern of damage seen. Drance (1988), proposed at least 
two mechanisms of glaucomatous optic nerve injury: 
1) The Ischaemic theory postulates that compromise of the microvasculature of the axons 
in the optic nerve head plays a role (Figure I.4a; l.4b ), possibly via 
a) loss of capillaries 
b) alteration m capillary blood flow 
c) blood vessel structural changes that disturb the delivery of nutrients or removal of wastes 
and metabolic products from the axons 
d) dysregulation of blood flow and/ or 
e) delivery of damaging vasoactive substances to the blood vessels of the optic nerve head 
(Kanskj. 1999). 
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This 'pressure-independent' mechanism could be responsible for localised visual function 
loss, with chronic ischaernia a possible risk factor. Moreover, ocular vasospasm may cause 
recurrent ischaernic damage to the optic nerve (Drance 1988). 
A. 
' . ,._.__, __ 
... 
'' • ~ ~ , : '. 
... 
·. 
Figure 1.4a. Histology section of the optic nerve head. LC, lamina cribosa; A&V, 
central retinal artery and vein; SAS, subarachnoid space (Forrester et al, 1999 pp48). 
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Figure I.4b Blood supply of the optic nerve (Forrester et al, 1999 pp48). 
2) The Direct Mechanical theory suggests that chronically elevated IOP directly damages 
the ganghon cell axons as they pass through the lamina cnbrosa by inducing collapse or 
deformation of the lamina plates (Figure I.4c). Tbis can impmge dtrectly on nerve fibres 
and compress vasculatures, resulting in inadequate delivery of nutrients to the axons in the 
optic nerve head (Kanski 1999). Another possibility is apoptotlc death of retinal ganglion 
cells, associated with IOP via a yet unidentified cellular pathway (Wiggs 2000). This 
'pressure-dependent' mechanism could account for diffuse visual function loss, with elevated 
IOP as the main risk factor (Drance 1988). 
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3 
Figure I.4c. Sectional view of optic nerve head in glaucoma (Bron et al, 1997 
pp497). 
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I.V GLAUCOMA INHERITANCE & FAMILY HISTORY 
"Hereditary glaucoma" was first reported by von Graefe in 1869. In 1941, Duke-Elder 
(1941) described "familial glaucoma", a type of glaucoma that was inherited in a dominant 
manner. To date, many studies have examined familial aggregation, inheritance and modes of 
transmission in selected families across the world (Brezin 1997; Litcher 1997; Angius 1998). 
Cross-sectional epidemiological studies have shown that 45-55% of POAG patients report a 
positive family history of glaucoma (Mitchell 1996; McNaught 2000; Williams-Lyn 2000), 
which is a risk factor for progression of ocular hypertension into POAG (Tielsch 1994; 
Nem~sure 1996; Quigley 1994; Rosenthal 1985; Leske 1996). Early evidence of glaucoma 
inheritance was observed in twin studies on monozygotic twins, which demonstrated 
concordance for POAG, although there have been exceptions (Teikari 1987). Concordance 
was higher between identical twins compared with fraternal twins, but the estimated genetic 
association was relatively weak in many cases, indicating a potential role for additional 
nongenetic or environmental factors (Armaly 1967). 
Many pedigrees of POAG have since been studied, but only some seem to follow simple 
Mendelian autosomal dominant transmission through several generations (Frey and Posner, 
1952; Francois 1961). Statistically, 50% of all offspring of an index case should be affected, 
but the prevalence is often found to be much lower in POAG, around the order of 10% 
(Wolfs 1998). Incomplete penetrance and a subtle phenotype have been suggested as a 
possible explanation Gay and Patterson 1970). Furthermore, autosomal recessive inheritance 
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patterns have also been suggested, particularly from the identification of cort:icosteriod-
induced ocular hypertension in 1963 (Becker and Mills 1963) and from advances m 
understanding of primary congenital glaucoma (Gencik 1998). The simple Mendelian modes 
of inheritance cannot adequately explain transmission in many cases of POAG, and there ls 
growing support for a multi.factorial model in which multiple genes act together with certain 
unidentified environmental factors Q"ay and Patterson 1970; Merin and Morin 1972). These 
varied findings support the premise that POAG comprises a spectrum of diseases rather 
than one clinical entity, with different forms displaying varying modes of inheritance. 
The results of the various family studies on POAG are difficult to compare because of 
differences in method of case ascertainment, definition of glaucoma, age criteria for 
participation, and number of years of follow-up. Often, only a family history was taken into 
account, or a limited number of family members were examined. These studies relied almost 
exclusively on observational data and used anamnest:ic recollections of POAG status in 
relatives to estimate heritability, thereby introducing selection bias (Nguyen 2000). 
Studies using multivariate analytic techniques have added supportive evidence for the role of 
family history as a significant risk factor (Wilson 1987; Drance 1973), estimating that a 
positive family history of glaucoma gives a 3-fold increase in risk of developing POAG 
(Leske 1996; Leske 1983; Leske 1995; Tielsch 1994). The Blue Mountains Eye study in 
Australia, which utitlsed a multivariate model and adjusted for age, gender, and other 
variables, also found that a first-degree family history of glaucoma is significantly associated 
with a previous diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OH) (OR 
3.6; Cl 1.8-7.2) (Hourihan 1999). Similarly, the Visual Impairment Project found positive 
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family history to be the strongest risk factor for glaucoma after adjusting for age (OR 3.1; 
95%CI 1.6-5.3)(Weih 2001). 
There is an increased prevalence of POAG among first-degree relatives of patients with the 
disease, with as many as 2.8% to 13.5% being affected compared to a prevalence of 0.5% to 
2% in the general population (Perkins 1974; Francois 1966; Becker 1960; Shaffer 1965; 
Nguyen 2000). 
In a Dutch population-based study in Rotterdam, glaucoma status was ascertained by visual 
field defects and cup-disc ratios of 0. 7 or higher or asymmetry of 0.3 or higher between both 
eyes (Wolfs 1998). The prevalence of glaucoma was 10.4% in siblings of patients compared 
with 0.7% in siblings of controls; it was 1.1 % in offspring of patients compared to 0% in 
offspring of controls. That is, a person's risk of POAG was increased by a factor of 2 1f a 
parent had POAG and a factor of 4-15 if a sibling had POAG (Kanskl 1999; Wolfs 1998). 
The lifetime risk of glaucoma was 22% in relatives of patients with glaucoma, almost 10 
times higher than in controls (2.3%), yielding a risk ratio for glaucoma of 9.2 (95% Cl 1.2-
73.9) (Wolfs 1998). The authors suggest that at least 1/6 of all glaucoma in the general 
population may be caused by a genetic component, while other non-genetic factors 
determine overall occurrence to a great extent. Although the results were statistically 
significant, the number of cases was small (n=48), which reduced statistical power and 
created wide confidence intervals (Wolfs 1998). 
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A more recent study objectively diagnosed POAG by dividing patients into three categories 
using IOP, field and disc changes (Nguyen 2000). The investigators found that siblings of 
POAG patients had the highest risk (64.7%) of developing POAG compared with children 
(13.2%) or other blood relatives (22.2%). The authors attnbuted the higher proportion of 
affected family members in the study to possible inclusion of families with two or more 
members with POAG, thereby introducing selection bias in favour of heritable forms of the 
disease. Another important shortcoming of the study is the poor rehability of perllnetry and 
the fact that only 37.2% of relatives returned for repeat visual field testing (Nguyen 2000). 
Nevertheless, the study supports the view that family history is a strong risk factor for 
developing POAG. 
Additional evidence of a genetic origin is supported by the familial occurrence of several 
mdependent ocular parameters associated with POAG, such as increased IOP level, 
abnormal optic cup size and reduced facility of aqueous outflow (Tielsch 1991), which 
appear to be genetically determined (Armaly 1967; Armaly 1968). It is interesting to note that 
in the Rotterdam study, enlarged cup-disc ratio, not IOP, was the earliest and most 
prominent feature of familial aggregation (Wolfs 1998). 
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The accuracy of a reported family history of glaucoma was mvestigated by McNaught and 
colleagues (2000), who questioned 41 index cases about their prior knowledge of any family 
history of POAG and compared this to the rate of glaucoma identified as a direct result of 
examination. Even in large pedigrees, 27% of previously diagnosed POAG patients were 
unaware of their positive family history, suggesting that a higher percentage of adult POAG 
may be inherited than reported (McNaught 2000). In a greater Toronto multiethnic 
popu).ation, the accuracy was found to be highest for first-degree relatives 
(parents/ siblings/ children) and lower for second-degree relatives 
(grandparents/ aunts/ uncles) or third-degree relatives (great-grandparents, great-aunt/ uncle, 
first cousins) (Williams-Lyn 2000). 
Indeed, "a positive family history is a useful risk marker for developing POAG, but is subject 
to recall, selection and survival bias as well as community under-diagnosis of glaucoma which 
tend to underestiinate the genetic influence on the prevalence of the disease" (Mitchell, in-
press). Thus it appears that POAG is often inherited, probably in a multifactorial manner. The 
responsible gene is believed to show a lack of penetrance and a variation in expressivity in 
some families, and often exhibits features of local founder effects (Brezin 1998) in different 
populations (Pang 2000; Fmgert 1999). 
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I.VI GLAUCOMA GENETICS 
Recent advances in molecular genetics and genetic mapping have resulted in an expanding 
number of novel genes being identified (Lichter 1994; Della 1996). 
In 1993, studies by Johnson and associates (1993) and Sheffield and associates (1993) of an 
American family with, primarily, JOAG led to mapping of the first POAG locus (Glaucoma 
1A or GLC1A) to chromosomal region 1q21-q31 (Figure 1.5). Linkage of JOAG to GLC1A 
was confirmed by later studies of additional families 0 ohnson 1996; Richards 1994; Graff 
1995; Wiggs, 1995). Subsequent studies showed that GLC1A is also responsible for a subset 
of adult-onset POAG (Meyer, 1996; Morissette 1997). 
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Figure 1.5 A pedigree of autosomal dominant juvenile glaucoma. Individuals 
affected by glaucoma are indicated with filled symbols. Half-filled symbols 
represent ocular hypertension. X = individuals examined by the original authors 
Gohnson et al, 1993). 
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In 1997, Stone and 14 colleagues from seven laboratories reported the identification of a 
trabecular meshwork-induced glucocorticoid response (TIGR) gene associated with JOAG 
(Figure 1.6). One of its proteins, originally called TIGR, showed time-dependent induction 
with· dexamethasone treatment over several weeks (Polansky, 1997). In the same year, 
Kubota and associates (1997) discovered a protein associated with the cytoskeleton in the 
retina, which they termed myocilin (MYOC) because it shared homologous regions with 
myosin. This turned out to be the same gene and protein that Nguyen and colleagues (1998) 
had described and named TIGR. In 1998, the Human Genome Organization Genome 
Database Nomeclature Committee assigned the gene the name myocilin, abbreviated MYOC 
(Craig 1999). 
Figure 1.6 TIGR gene (Johnson, 2000). 
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To date, over 26 mutations in MYOC (previously TIGR) have been described in some cases 
of adult-onset POAG Qohnson 2000). Indeed, other genetic mutations have also been 
reported in other forms of glaucoma as summarised in Table 1.2. For example, primary 
congenital glaucoma is associated with mutations in the CYP1B 1 gene on chromosome 2p21 
(GLC3A) (Stoilova, 1997) and an unidentified gene on chromosome 1p36 (GLC3B)(Akarsu, 
1996). Mutations in the FKHL7 gene on chromosome 6p25 is described in patients with 
Axenfeld-Rieger anomaly, which has at least 3 genetic loci (Craig 1999; Alward 2000). 
Table 1.2 Summary of genetic inheritance of glaucoma (Craig 1999; Raymond 1997). 
Glaucoma type 
Primary open-angle glaucoma 
JOAG & adult-onset POAG 
POAG (adult onset) 
POAG (adult onset) 
POAG (intermediate onset) 
POAG (adult onset LTG) 
POAG 
Primary congential glaucoma 
Developmental glaucoma 
Rieger syndrome 
AD iris hypoplasia 
Iridogoruodysgenesis 
syndrome 
Axenfeld-Reiger anomaly 
Iris hypoplasia 
(IGD) 
Familial glaucoma IGD 
Familial glaucoma with GD 
Rieger syndrome 
Other types 
Nail-patella syndrome 
Pseudoexfohation syndrome 
Pigment dispersion syndrome 
Locus 
GLC1A 
GLC1B 
GLC1C 
GLC1D 
GLC1E 
GLC1F 
GLC3A 
GLC3B 
RIEG1 
IRID2 
RID1 
RIEG2 
NPS1 
Location 
1q24.3-q25.2 
2cen-q13 
3q21-q24 
8q23 
10p15-p14 
7p35-36 
2p21 
lp36 
4q25 
6p25 
13q14 
9q34 
2p16 
Gene 
MYOC/TIGR 
NYI 
NYI 
NYI 
NYI 
NYI 
CYP1B1 
NYI 
PITX2 
FKHL7/ 
FREAC3 
NYI 
Ll\1X1B 
NYI 
(PDS) GPDS1 7q35-36 NYI 
PDS GPDS2 18911-21 NYI 
AD - autosomal dominant; GD - goniodysgenesis;; JOAG - juvenile-onset open-angle glaucoma; LTG - low-
tens10n glaucoma; NYI - not yet identified; POAG - primary open-angle glaucoma. 
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I. VII PRIMARY OPEN-ANGLE GLAUCOMA GENETICS 
Reports have confirmed that mutations in GLC1A are also responsible for approXllnately 3-
5% of adult POAG m the general population (Morissette 1997; Meyer 1996; Alward 1998; 
Fingert 1999). In a recent collaborative study, the specific mutations found in different 
populations varied, mostly due to local founder effects; however, the overall frequency of 
disease-causing mutations in MYOC was similar across the five populations representing three 
racial groups (Fingert 1999). 
The majority of mutations described have been missense mutations m the third exon, 
encoding an evolutionarily conserved olfactomedin-homology domain of GLC1A (Adam 
1997). Specific mutations appear to correlate with severity of glaucoma and may act by a 
dominant negative mechanism. The most common mutation (Gln368STOP) was found to 
be associated with POAG with mean age of onset of 59 years and mean highest IOP of 30 
mmHg (Alward 1998; Allingham, 1998). This mutation causes a relatively mild form of 
glaucoma compared to most other mutations in the GLC1A gene, such as the Thr377Met 
mutation (Alward 1998; Mackey, in-press) and the Thr448Pro mutation (Xokoyama 1999). It 
has ~eady been shown that the Gln368STOP mutation has penetrance which increases WJ.th 
advancing age (Angius 2000; Craig 2001). However, further studies are needed to establish 
whether additional factors are required for the development of glaucoma. 
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In some pedigrees, the phenotype showed considerable variability in severity and age of onset, 
with some genotypically affected members exhibiting adult-onset POAG (Dubois 1997; Meyer 
1996). Moreover, a study in a very large pedigree with 71 affected individuals showed that an 
Asp480Lys mutation segregates with POAG (Brezin, 1998). There is now a belief that other 
factors (genetic or environmental) may modify the phenotype of GLC1A-linked glaucoma. 
Indeed, genetic heterogeneity of POAG and linkage to GLC1A confer a highly increased risk 
of not only developing POAG but also having severe glaucomatous optic neuropathy (Brezin 
1997). 
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Figure 1.7. Schematic diagram of human myocilin protein CTohnson, 2000). 
The pathophysiology of myocilin is yet to be elucidated. The GLC1A gene (Figure 1.7) 
consists of three exons that encode a 504 amino acid protein with an olfactomedin-like 
domain and a leucine zipper motif hypothesised to mediate protein-protein interactions 
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(Shimizu 2000). Myocilin is an endogenous glycoprotein with molecular weights of 66 kD 
(glycosylated form) and 55 kD (nonglycosylated form)(Polansky, 1997) that may function as 
a heat shock protein which protects tissues during stress. It is normally present in a variety of 
ocular and nonocular tissues, mcluding trabecular meshwork, cornea, retina, optic nerve, 
ciliary nerves, and the heart, skeletal muscle, stomach, thyroid and lung (Fingert 1998). 
Expression studies have shown that myocilin 1s shown in the trabecular meshwork of both 
normal and glaucomatous eyes (Takahashi et al 2000), where the intracellular protein 
colocalises with microtubules (Mertts et al 1999). However, it may be present in more 
regions and have more intense labelling in the glaucomatous eyes (Lutjen 1998). 
Recent studies suggested that GLC1A mutations led to elevated IOP by trabecular 
dysfunction and reduced aqueous outflow (Nguyen 1998; Lutjen 1998; Wilkinson 1998). 
Although myocilin is also expressed in the ciliary body, which ls responsible for aqueous 
production (Craig 1999). A variant in the promoter region of the nitric oxide synthase 
(NOS) gene has been found in a significant percentage of familial POAG. Although this 
genetic polymorphism may not be of physiologic significance, NOS catalyses endothelium-
derived nitric oxide, a potent modulator of vascular tone in ophthalmic artery, which can 
contribute to lschaemic damage of optic nerve head (Adam 1997). 
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There have been significant nnpediments to establishing linkage for autosomal dominant 
POAG in some pedigrees (Coote 1966) for the following reasons: 
• 50%-60% of glaucoma is not diagnosed in the community (Wensor 1998; Weih 
2001) 
• Diagnostic uncertainty of glaucoma and subtle phenotypes 
• Late onset and late age of diagnosis 
• Affected parents are often deceased 
• Little contact with affected cousins or second cousins (Mackey, personal 
communication 2001). 
Despite these problems, Table 1.2 illustrates that sigruficant linkage has been established to 
at least five chromosomal regions in addition to GLC1A in some families with POAG, 
including markers in the region 2cen-q13 (designated GLC1B)(Stoilova 1996; Allingham 
1998), 3q21-24 (GLC1C)(Wirtz 1997), 8q23 (GLC1D)(Trifan 1998), 10p15-p14 
(GLC1E)(Sarfarazi 1998) and most recently 7q35-36 (GLC1F)(Wirtz 1998). The 
contribution of these loci is yet to be determined as the specific genes have not yet been 
identified but they tend to support an autosomal dominant mode of inheritance. It is 
interesting to note that some cases of GLC1B and GLC1E are associated with normal-
tension glaucoma, suggesting a different pathophysiological mechanism (Craig 1999). 
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I.VIII GLAUCOMA INHERITANCE IN TASMANIA 
Figure 1.8. Tasmanian map 
Figure 1.9. Lady Nelson was one of the earliest tall ships transporting convicts from 
United Kingdom to Tasmania 
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An island community such as Tasmania ( Figure 1.8 ) or Iceland is highly suitable for 
genetic research. Finding large pedigrees was made easier by the following features (Mackey, 
personal communication 2001): , 
1) Tasmania 1s a, somewhat isolated Australian island state that was settled by Europeans in 
1803. Today, it has a 'captive' population of approximately 470,000 (Figure 1.9). 
2) A large Founder effect from early settlers with large families within the population 
(Figure 1.10) (Brezin 1998). 
3) Comprehensive genealogical records, with 1 in 30 Australians able to trace their family tree 
back to the original immigrants. Active genealogical societies have created a computerised 
database of births, deaths and marriage records. 
4) A high standard of ophthalmic care to over 5000 Tasmanians affected by glaucoma, 
allowing a reliable diagnosis of glaucoma and ensuring at least 50% of cases are identified. 
The Glaucoma Inheritance Study in Tasmania (GIST) score was developed to give a relative 
likelihood of glaucoma to family members as it reflects objective physician grading of 
intraocular pressure, optic disc changes and visual field defects (Coote 1996). Please refer to 
chapter IV for more details. 
28 
Figure 1.10. Port Arthur - early convicts settlement in Tasmania. 
I.IX SUMMARY 
• Glaucoma is a highly heterogeneous group of eye disorders, the most common type of 
which is POAG in developed countries. 
• Known as the "sneak thief of sight", up to 50%-60% of people with glaucoma in the 
community remain undiagnosed (Mitchell 1996; Quingley 1996; Wensor 1998). 
• Over 50% of all glaucoma is familial (Mitchell 1996; McNaught 2000). 
• A positive family history of glaucoma gives a 3-fold increase in risk of developing 
POAG (Leske 1996; Tielsch 1994; Hourihan 1999). 
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• qver 27% of diagnosed POAG patients are unaware of theu positive family history 
(McNaught 2000). 
• Mutations in GLC1A (MYOC) are identified in approximate 3-5% of adult POAG in the 
general population, which may exhibit local founder effects (Fingert 1999). 
• Significant linkage has also been established to at least five additional loci (GLC1B-F). 
• The pathophysiology of myocilin is unclear, but the current multi.factorial model suggests 
that other factors (genetic and environmental), as yet uncharacterised, may modify the 
expression of the POAG phenotype in GLC1A pedigrees. 
In chapter II, the Review of Related Literature highlights the current understanding of the 
associations between total POAG and various clinical risk factors; in chapter III, the 
Conceptual Framework and Hypotheses are stated; and in chapter IV, the Methodology is 
described. 
In chapter V, the Results and Statistical Analysis comparing familial and sporadic glaucoma 
groups are presented; in chapters VI - XV, the Results, Statistical Analysis & Discussion on 
various clinical risk factors are dissertated; and in chapter XVI, the Conclusion, Implications 
and Recommendations for future research and practices are examined. 
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CHAPTER II 
REVIEW OF RELATED LITERATURE 
'That men do not learn very much from the lessons of history is the 
most important of all the lessons that history has to teach. " 
(Aldous Huxlry) 
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II.I OCULAR RISK FACTORS 
II.I.I Intraocular Pressure (IOP) 
Elevated IOP 1s generally believed to be a major risk factor for glaucoma (Vaughan 1992; 
Berson 1993; Leske 1995; Tielsch 1991; Leske 1983). The nsk of optic nerve head damage 
increases as the IOP increases. For IOP of 16-21 mmHg, the prevalence of POAG is 1.5%. 
As IOP rises to 22-29 mmHg, the prevalence is 8%. At IOPs of over 30 mmHg, the 
prevalence rises to 25% (Kanski 1999). As found in the Blue Mountains Eye Study (Mitchell 
1996), the steady increase in POAG prevalence with increasing IOP and the steep rise in nsk 
with IOP above 23 mmHg suggests a causal relation, particularly at high IOPs. A similar 
trend was reported in the Baltimore Eye Survey (Tielsch 1991), which confirms a continuous 
nature of the I OP-glaucoma relationship, with no clear IOP level to distinguish between so-
called high- and low-tension glaucoma (Mitchell 1996). POAG may occur throughout the 
range of IOP levels (Leske 1983; Klein 1991; Sommer 1991). Conversely, glaucomatous 
changes do not always occur with raised IOP (ocular hypertensive individuals), and 
glaucomatous change can be observed in eyes with IOP within the normal range (normal-
tension glaucoma) (Berson 1993). 
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A possible limitation of these studies is the "snapshot nature of a single presenting IOP 
measure, which may not represent the peak or mean IOP or provide information on the 
duration of any elevation." This may explain the relatively low proportion of glaucoma cases 
with elevated IOP in the Blue Mountains Eye Study (Mitchell 1996). Furthermore, the lack 
of a one-to-one relationship between elevated '!OP and glaucomatous change (Dielemens 
1995), the occurrence of increased IOP after initial observation of disc abnormalities, and 
the lack of a clear unequivocal demonstration of the efficacy of IOP lowering in preventing 
progressive damage simply suggest other factors ~ntribute to the development of glaucoma. 
The Barbados Eye Study (Wu 1997) found that high systolic blood pressure (hypertens10n), 
diabetes, and older age were positively associated with IOP (P<0.01), as were female gender, 
darker complexion, higher pulse rate, higher body mass, seasonality, family history of 
glaucoma, current alcohol use, and current smoking. As a high IOP is a major risk factor for 
POAG, it would be reasonable to speculate that similar associations occur for both 
conditions. However, studies to date have demonstrated that only advancing age and self-
reported family history of glaucoma are significantly associated with both ocular 
hypertension and POAG, suggesting that gene-environment interaction is important in the 
pathogenesis of glaucoma (Wu 1997). Indeed, 7-8% of the population over the age of 40 
years have IOPs greater than 21 mmHg, but only 1 % of individuals with ocular hypertension 
(OH) will develop glaucomatous visual field loss each year (Kanski 1999). More recently, the 
Blue. Mountains Eye Study reported that after adjusting for systolic blood pressure and 
confounding effects of diabetes, glaucoma family history and myopia, age was not 
significantly associated with IOP (p<0.29) (Rochtchina 2002). 
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II.II NON-OCULAR RISK FACTORS 
II.II.I Age 
Earlier studies demonstrated a lugher prevalence of POAG with advancing age (Hollows 
1966; Kahn 1980; Mason 1989), and these have been confirmed by many recent population-
based cross-sectional studies (Leske 199 5; Wang 1997; Klein 1992; Dielemens 1994; Mitchell 
1996; Wensor 1998; Angius 2000; Klaver 1998; Mukesh 2002). The Collaborative Glaucoma 
Study (Armaly 1980) also identified age as the major predictor of glaucoma mcidence. 
Although an independent age effect on IOP is controversial (Wu 1997; Rochtchina 2002), it 
is likely that the optic nerves of the elderly are more susceptible to damage for reasons other 
than higher pressure (Wilson 1994). 
II.II.II Gender 
A few incidence studies noted higher rates of POAG in women (Bengtsson 1989; Teikan 
1989), but population-based studies have yielded conflicting results on sex-specific glaucoma 
prevalence. There is a higher rate in white men in some studies (two-fold male to female risk 
in the Framingham Eye Study (Leibowitz 1980) and the Long Island study reported a male 
odds ratio of 1.69 (Leske 1996)), but not in others (Mason 1989; Tielsch 1991; Leske 1983; 
Kahn 1980; Hollows 1966; Klein 1991; Alward 2000). 
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Furthermore, the Blue Mountains Eye Study found a higher prevalence of POAG in 
Australian women in comparison to men (OR 1.5; Cl 1-2.2)(Mitchell 1996). In contrast, the 
Melbourne Visual Impairment Project found no relationship between POAG and gender 
(Wensor 1998; Weih 2001). 
The Barbados Eye Study found a higher rate of POAG in black men, who show age-specific 
differences between gender. However, the authors concluded that this could be due to 
differences m reporting secondary to some unidentified bias such as differences in reportlng 
family history, or there may exist a real gender difference in risk (Leske 1995). Further 
corroborating evidence is needed. 
II.II.III Race 
Clinic-based studies have reported a higher proportion of black patients in glaucoma clinics 
in comparison to general eye clinics (Martin 1985; Wilson 1987), and a greater proportion of 
black patients with glaucoma undergoing glaucoma surgery as compared to medical therapy 
(Coulehan 1980). 
Many large population-based studies examined prevalence of POAG in populations that are 
largely white communities, including the United Kingdom (Hollows 1966; Coffey 1993), 
United States of America (Kahn 1980; Kahn 1980; I<Jein 1992), Sweden (Bengtssoh 1981), 
Holland (Dielemans 1994) and Australia (Mitchell 1996; Wensor 1998). 
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A number of recent surveys have also included Asian (Shiose 1991), multiracial (Tielsch 
1991) or black (Leske 1994) communities in which at least a 4-5 tunes higher prevalence rate 
has been found (Flammer 1998). 
II.II.IV Demographics 
The Melbourne Visual Impairment Project reported no significant association between age, 
gender, or residential area and use of glaucoma medications (\Veih 1998). Moreover, a 
previous diagnosis of open-angle glaucoma (OAG) or OH was not significantly associated 
with decreased socio-economic status, the use of community support services or impaired 
mobility (Hourihan 1999). 
II.III CLINICAL RISK FACTORS OF POAG 
Several epidennological studies have began to identify groups at risk of developing POAG, 
and have led to formulation of hypotheses and the elucidation of potential risk factors. 
Although no aetiological factor is yet identified, some risk factors such as hypertension and 
diabetes mellitus may be modifiable through intervention and disease-prevention strategies. 
Others, such as family history, age, gender and race, cannot be modified, but do facilitate 
identification of those at highest risk of glaucoma blindness for whom close medical 
supervision and follow-up is beneficial. This may also affect rate of progression of disease 
and be helpful in guiding therapy (\Vilson 1994). 
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II.III.I Systemic Blood Pressure (Hypertension) 
The data regarding an association between POAG and hypertension are conflicting. Many 
studies have reported a posi11ve association between increased blood pressure and raised 
IOP (Leske 1983; Bulpitt 1975; Kahn 1977; Klein 1981). However, there is no consensus 
either regarding the possible relationship of POAG to high blood pressure or on the 
possible effects of anti.hypertensive treatment (Wilson 1987; Drance 1973; Morgan 1975). 
Furthermore, it has been criticised that earlier clinic-based studies reporting positive 
association may result from selection biases or from the confounding effect of age, IOP or 
other vanables. 
Results from population-based studies have also differed. In the Baltimore Eye Survey, there 
was no significant association between hypertension and POAG. Race-adjusted odds ra11os 
tended to be lower at younger ages and higher at older ages, suggesting that hypertension is 
protective at ages under 60 and damaging at older ages (Tielsch 1995). However, the results 
were not statistically significant. 
In the smaller Rotterdam POAG Study (n=42), a positive relationship between hypertension 
and POAG was found only in cases with high IOP; however the odds ratio was not 
significant (Dielemans 1995). Furthermore, the Barbados Eye Study (n=302 definite cases of 
POAG) found that an elevated systolic blood pressure, regardless of treatment, was 
associated with POAG at ages under 70 years; however the association was weak and did not 
persist after age-sex adjustment or multi.variate analysis (Leske 1995). More recently, the 
37 
Long Island Study also did not support the hypothesis that systemic hypertension 
independently increases the risk of POAG field defect (Leske 1996). 
It is of interest to note that both the Barbados Eye Study and the Long Island Study found a 
significant association between POAG and low perfusion pressure ~ow diastolic blood 
pressure-IOP differences). An association between low systolic and diastolic blood pressure 
to IOP ratios has also been documented (Leske 1995; Leske 1996). The role of vascular risk 
factors is consistent with findings of low blood pressure to IOP ratios, but this could be 
explained by the high IOP in POAG rather than by a relatively low blood pressure. 
Moreover, the relationship between systemic blood pressure and IOP may not accurately 
reflect the local perfusion pressure at the optic disc. At present, therefore, there is 
insufficient evidence to support the role of hypertension as a strong independent risk factor 
for POAG. 
II.III.II Diabetes Mellitus 
The association between diabetes mellitus and POAG is still controversial. 
A number of studies have reported an increased prevalence of individuals with abnormal 
glucose metabolism among patients with glaucoma compared to the general population 
(Armstong 1960; Armaly 1969), and subsets of individuals with abnormal glucose 
metabolism have significantly greater risk of developing glaucoma (Armaly 1969; Katz 1988). 
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Furthermore, an elevated mean IOP 1n patients with diabetes compared to those without 
diabetes has also been documented (Becker 1971; Kass 1978; Klein 1994). However, a 
similar number of studies did not support such associations (Bengtsson 1981; Armaly 1980; 
Mapstone 1985; Bouzas 1971). Tielsch and associates (1995) have suggested that the positive 
associa11on found in some previous clinic-based studies was due to selection bias. As both 
diabetes and glaucoma are commonly underdiagnosed, there is significant potential for 
selection bias when ascertainment is based only on self-presentation to a doctor. People with 
diabetes are more likely to be seen by an ophthalmologist than people without diabetes and 
hence are more likely to have glaucoma detected. 
To date, only a few population-based studies have examined the relationship between the 
two disorders (Kahn 1980; Kahn 1980; Klein 1994; Tielsch 1995; Dielemens 1996; Mitchell 
1997). The Baltimore Eye Survey failed to confirm a significant association between diabetes 
and POAG in 161 black and white participants with definite or probable POAG (age-race 
adjusted OR 1.01) (Tielsch 1995). After stratifying participants into previous and newly-
diagnosed glaucoma cases, the study found a weak association between diabetes and POAG 
for patients who knew they had glaucoma (age-race adjusted OR 1.71), but no association 
for those with newly diagnosed glaucoma (age-adjusted OR 0.60). Thus giving support to the 
likelihood of selection and recall bias in earlier studies. 
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In contrast, the Rotterdam Eye Study found a threefold increased presence of high-tension 
glaucoma (OR 3.11; Cl 1.2-8.66) among newly diagnosed diabetic patients (both men and 
women) (D1elemens 1996). The Blue Mountains Eye Study which had 108 glaucoma cases 
(Mitchell 1997), diagnosis of glaucoma was made if matching visual field and optic disc 
cupping were present, independent of any prior glaucoma diagnosis or therapy or any 
particular lOP level. This minimised diagnosis bias. Fasting plasma glucose levels were 
ascertained, and if higher than 7.8 mmol/l, diabetes was diagnosed. Similar to the results 
reported in the Beaver Dam Study (Klein 1994), glaucoma prevalence was approximately 
doubled in people (both men and women) with diabetes diagnosed from history or 
biochemical evidence of elevated plasma glucose levels (5.5%), compared with those without 
diabetes (2.8%; age-gender adjusted OR 2.12; 95%Cl 1.18-3.79). After adjusting for lOP 
(higher of the two eyes), age and gender, the association between glaucoma and diabetes 
persisted, albeit slightly reduced (OR 1.77; Cl 0.96-3.26). 
Conversely, in the same study, diabetes "'.as present in 13% of people with glaucoma (and 
16.7% of those with a previous diagnosis of glaucoma; OR 2.82 Cl 1.35-5.87) compared 
with 6.9% of those without glaucoma. A weaker, but non-significant association between 
newly diagnosed glaucoma and diabetes remained (OR 1.47; Cl 0.58-3.73). This seems to 
support the suggestion that selection or discovery bias, such as more frequent eye 
examinations amongst diabetic patients, may partly explain the association between diabetes 
and glaucoma. However, 67% of those with both diseases had glaucoma diagnosed before 
the diabetes, suggesting that selection bias is probably less important than anticipated 
(Mitchell 1997). 
40 
The role of genetic factors in the association has been questioned by the study. The 
significant relation between diabetes and glaucoma persisted after adjusting for family history 
of diabetes, age and gender in a logistic regression (OR 2.41; Cl 1.30-4.44). The relation was 
also maintained after adjusting for a family history of glaucoma, age and gender (OR 2.22; Cl 
1.24-4.53) (Mitchell 1997). 
II.Ill.III Migraine Headache 
In a neurologic study of 27 patients, Corbett and associates (1985) noted that nearly half of 
their patients with low-tension glaucoma gave a history of common or classic migraine 
headache. In their subsequent case-control study (Phelps 1985), the authors found that the 
increased prevalence of headache in the low-pressure glaucoma group compared with the 
normal group was statistically significant for individuals aged 70 years or older (P=0.04). 
Several researchers have hypothesised that the glaucomatous damage of optic nerve head 
may be caused by migrame-related transient vasospastic alterations of cerebral or meningeal 
blood flow, ischaemic vascular diseases (Drance 1973) and blood coagulopathies (I<laver 
1985; Winder 1977). However, in a case-control study, Usui (1991) failed to find a 
statistically significant correlation in migraine prevalence between either low-pressure 
glaucoma, POAG, or normal subjects. Moreover, a multivariate study found no difference 
between low-tension and high-tension glaucoma groups with respect to organic vascular 
pathologic findings (Carter 1990). In the population-based Beaver Dam Eye Study, no 
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association between POAG and migraine headache was found (Klein 993). Despite 
continuing controversy, it is reasonable to suggest that local perfusion pressure at the nerve 
head is an important variable in the development of POAG, regardless of lOP (Wilson 
1994). 
In a more recent Blue Mountains Eye study, for all age groups combined, there was no 
significant association between typical migraine headache (16.7% reported history of 
migraine) and POAG (16.6%) (OR 1.3; 95% Cl 0.8-2.2), after multivariate adjustment 
mcluding glaucoma family history, diabetes, pseudoexfoliation, and hypertension (Wang 
1997). 
After stratifying the subjects into 10-year age groups, Wang and associates found increased 
odds for POAG among people having a history of typical migraine and aged 70-79 years 
(OR 2.5; Cl 1.2-5.2), after adjusting for variables associated with POAG (Wang 1997). 
Furthermore, the association was slightly stronger for high-pressure POAG (>21mmHg) 
cases (OR 2.7; 1.1-5.6) (Wang 1997). 
The authors concluded that other influences such as genetic factors might be important and 
if an association between migraine and POAG exists, it is likely to be only modest (Wang 
1997). 
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II.III.IV Cigarette Smoking 
Glaucoma has been reported to be associated with increased alcohol consumption (Kahn 
1980) and cigarette smoking (Wilson 1987). However, in the Blue Mountains Eye study, 
smoking was demonstrated not to be significantly associated with POAG, and adding 
smoking (current versus non-current or ever versus never) into the multivariate model 
comparing migraine and POAG did not alter results (Wang 1997). 
II.III.V Corticosteroid Responsiveness 
Many studies have demonstrated that the use of oral or topical ophthalmic corticosteroids in a 
minority of people, called 'steroid responders', can lead to varying degrees of elevated IOP and 
predispose them to developing POAG (Becker 1963; 1965; Williamson 1969; Mitchell 1999). 
The normal population can be classified into three groups according to their IOP 
responsiveness to datly topical administration of a potent corticosteroid (betamethasone or 
dexamethasone) for 4-6 weeks (Clark 1995; Richardson 1997). The majority (two-thirds) of 
people in the population show no response at all (Armaly 1965; Becker 1964; Foon 1977). 
These "non-responders" develop pressure rises ofless than 6 mmHg and IOPs ofless than 20 
mmHg. On the other hand, 4-6% of the population are categorised as "high responders", 
demonstrating IOP increases of more than 15 mmHg and IOPs greater than 31 mmHg. The 
intermediate group of "moderate responders", comprising approximately one-third of the 
population, exhibit more delayed and lower pressure rises of 6-15 mmHg with IOPs between 
20 and 31 mmHg. 
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An earlier study reported that nearly all persons with a diagnosis of POAG were moderate-
to-high responders to corticosteroids (Becker 1964). Ninety percent of patients with POAG 
were high responders to a 6-week course of topical ocular betamethasone, during wluch 
their IOPs showed marked elevation (>30mmHg). The remaining 10% of patients with 
POAG showed moderate response with a moderate elevation of IOP (22-30mmHg). Steroid 
responders in the normal population were also shown to have a higher risk of developing 
POAG over time (Lewis 1988; Kitazawa 1981). 
A genetic basis for steroid-induced ocular hypertension was postulated by some investigators 
in the 1960s (Becker 1964; Armaly 1967), but disputed by others (Francois 1966). Clinic 
studies have demonstrated that inheritance of a steroid response may have an autosomal 
recessive pattern and may be associated with inhentance of glaucoma (Davies 1968; Bartlett 
1993) in a rather complex manner (Clark 1995). It is interesting that both siblings and 
offspring of patients with POAG have increased responsiveness to steroids (30 and 25% 
respectively are high responders) (Richardson 1997). Recently, the discovery of the 
trabecular meshwork-induced glucocorticoid response (TIGR) gene or J\1YOC at the 
GLC1A locus and its multiple disease-causing mutations in some 5% of hereditary glaucoma 
has added further support for the genetic basis (Sheffield 1993; Stone 1997; Fingert 1999). 
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Users of inhaled corticosteroids may also be at increased risk of OH and glaucoma. This 
association was noted in a health irisurance database study in Quebec (Garbe 1997; Garbe 
1998). The Blue Mountains Eye Study reported a strong association between ever use of 
inhaled corticosteroids and findings of glaucoma or OH in persons with a family history of 
glaucoma (OR 2.6; Cl 1.2-5.8). Moreover, the risk increased with higher doses (OR 6.3; Cl 
1.0-38.6) for persons who used more than four puffs per day (Mitchell 1999). However, no 
significant association was found for persons with no family history of glaucoma, adding 
further support for a genetic mechanism in the association. 
II.IV SUMMARY 
• POAG is positively associated with age and lOP. Black communities and female gender 
are probable nsk factors of POAG. 
• Conflicting evidence exists on the association between POAG and systemic 
hypertension. There is, however, more supportive evidence of an association between 
POAG and low perfusion pressure Oow diastolic blood pressure - lOP difference), and 
between POAG and low blood pressure to lOP ratios (Leske 1986; Leske 1995). These 
two latter relationships are not examined in the present study. 
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• The current literature suggests that POAG and diabetes mellitus are positively 
associated. There is a two- to three-fold increased risk of POAG among diabetic patlents 
and a two-fold increase in risk of diabetes among POAG _patients (Dielemens 1996; 
:Mitchell 1997). 
• · The association between POAG and migraine is less consistent and, if it does exist, it is 
likely to be modest (Wang 1997). Ocular vasospasm is a likely risk factor for POAG 
(Flammer 1992; Dran~e 1988), and may be associated with generalised vasospastic 
tendency manifested in migraine, Raynaud's phenomenon (cold extremities) and 
Prinzmetal angina (atherosclerosis). 
• There is no strong evidence for an association between POAG and smoking (Wang 
1997). 
• A preponderance of studies has demonstrated that nearly all glaucoma patients are 
moderate-to-high responders to topical corticosteroids. Steroid responders in the normal 
population are also at an increased risk of developing POAG (Lewis 1988; Kitazawa 
1981). Use of inhaled corticosteroids is also associated with POAG or OH (:Mitchell 
1999). 
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• Despite the number of large-scale cross-sectional epidemiologic studies exarruning the 
relations between total (familial and sporadic) glaucoma and various clinical risk factors, no 
sj:udy has yet investigated the potential links between familial POAG and the above climcal 
risk factors. This study aims to examine all 'glaucoma' patients in Tasmania and categorises 
them into familial and sporadic subgroups based on genealogic data and objective 
examinations. The prevalence of various risk factors in the two groups is compared and 
potential modifiers in the familial group are analysed. 
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CHAPTER III 
CONCEPTUAL FRAMEWORK & HYPOTHESIS 
"It is a good morning exercise for a research scientist to discard a pet hypothesis everydqy before 
breakfast. It keeps him young. " 
(Konrad Lorenz) 
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.) 
Strategies to eliminate the bhndness toll of glaucoma must be aimed at identifying 
undiagnosed glaucoma cases in the community to achieve early diagnosis and management 
before the onset of vision loss. Given the significant risks associated with a positive famtly 
history of glaucoma, it is the primary aim of tlns thesis to: 
* Seek evidence of differences in prevalence of known or potential risk factors between two 
populations classified as having glaucoma based on GIST scores of 0.7 or greater - the 
familial population defined by genealogic connection to known glaucoma sufferers and the 
sporadic population defined by the absence of genealogic connection to known glaucoma 
patients. 
Adjustment will be made for possible gender and age differences and for potential 
interactions amongst the various risk factors. 
If there is evidence against the null hypothesis of no difference in expected rates of risk 
factors between the two glaucoma populations, pairwise comparisons are employed to 
determine where the difference lie. 
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Further aims include: 
1. to compare the prevalence of risk factors between the two glaucoma populations at GIST 
scores of 0.7, 0.8, 0.9 and 1.0; 
2. to examine potential differences in the prevalence of risk factors between the sporadic 
glaucoma population and the familial glaucoma population at 1 •i, 2nd, 3'd and 4th degrees 
of connection (relationslup) to family members with POAG; 
3. to compare the prevalence of risk factors between the sporadic glaucoma population and 
the individual pedigrees of the familial glaucoma population; and 
4. to establish if the prevalence of risk factors differ between a no glaucoma ('controls') 
population as defined by GIST scores of 0.5 or less and a total glaucoma (familial & 
sporadic) population as defined by GIST scores of 0.7 or greater. 
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CHAPTER IV 
MATERIALS & METHODS 
"You know my methods) Watson . . . )) 
(M.emoirs of Sherlock Holmes) Sir Arthur Conan Dqyle) 
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This is a cross-sectional, retrospective study comparing the prevalence of various risk factors, 
such as hypertension, diabetes and migraines, in patients with familial POAG to the prevalence 
of the same risk factors in patients with sporadic or non-familial POAG, using a multi-stepped 
regression analysis. 
IV.I Study Population 
With the cooperation of ophthalmologists in Tasmania, an extensive review of the clinical 
notes of all patients attendmg all ophthalrmc practices in the state was performed, thereby 
creating a glaucoma registry for each ophthalmologist. Surveys inviting glaucoma patients 
(index cases) to participate in the study were directly mailed to 3800 Tasmanian patients who 
had been investigated or treated for 'glaucoma' over the previous 15 years. Furthermore, in 
order to cover the entire glaucoma population, surveys were chstnbuted throughout the state 
through ophthalmologists, optometrists, general practitioners, glaucoma support groups and 
pharmacies with additional general community awareness through local newspapers, radio 
and television media publicity. 
Written mformed consent (Appendix A) was obtained from patients to participate in the 
Glaucoma Inheritance Study, which was approved by the relevant ethics committees of the 
following institutions: The University of Tasmania (Hobart), the Royal Hobart Hospital 
(Hobart, Tasmania), and the Royal Victorian Eye and Ear Hospital (Melbourne, Victoria). 
This study is conducted in accordance with the Declaration of Helsinki and subsequent 
revisions. 
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Care was taken to ensure participants understood that they were under no obligations and 
were free to discontinue at any time. They were asked several times during the testmg 
procedures if they were happy to continue. 
In the surveys (Appendix B), participants provided information regarding their families and 
were asked if they had relatives with glaucoma and who their parents were. The index cases 
were· then followed-up with questions about their grandparents and 1f any family tree had 
bee~ traced in the family. With the assistance of a professional research genealogist using 
computerised family tree databases available in Tasmania, 309 pedigrees were reconstructed 
and the genealogy was extended by connecting with other index cases to complete family 
trees and to locate all descendants over 10 years of age to be invited for examination. 
As reported earlier, there are overlaps of different glaucoma pedigrees through 
intermarriages (Sack 1996). The multiple genotypes in individuals who had family members 
affec~ed with glaucoma on both the maternal and paternal sides of the family may partly 
explain the phenotypic heterogeneity in some families. Therefore, alternate parents or their 
families were also examined, particularly if the phenotype was atypical for the rest of the 
family. 
53 
The exclusion criteria were as follows: 
• presence of glaucoma other than POAG, such as angle-closure or pigmentary glaucoma 
(n=12; 0.3%) 
• <10 years of age, such as congenital glaucoma (n=223; 5.9%) 
• associated syndromes of anterior segment dysgenesis, such as nail-patella syndrome and 
aniridia (n=26; 0.7%) 
• presence of field defect or optic disc pathology other than POAG, such as macular 
degeneration, vascular/thrombotic events, optic disc drusen and cerebrovascular 
accident (n=26; 0.7%) 
• glaucoma highly distinct from the pedigree phenotype (n=5; 0.1 %) 
• inability to complete study protocol including refusals and deaths (n=68; 1.8%) 
3290 subjects (86.6%) participated in the 5-year study ending November 1998 (age range 10-
106 years). 360 subjects were excluded, giving a final number of eligible participants of 2930 
(77.1%). 
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These individuals were categorised into four groups based on the GIST score as follows: 
Table IV.1- Distribution of subjects into familial glaucoma, sporadic glaucoma, 
borderline and unaffected 'controls' groups based on GIST scores and genealogic 
data. 
Unaffected Borderline Familial Glaucoma Sporadic Glaucoma Total 
GIST_:S0.5 GIST=0.6 GIST~0.7 GIST~0.7 
742 486 854 848 2940 
There are 1667 males (average age 65 years) and 1263 females (average age 66 years). 
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IV.II Procedures/Instrumentation 
As the identity of all glaucoma genes and associated disease-causing mutations is not yet 
completed, we are still dependent on clirucal examination for detection of glaucoma using the 
three standard tests of tonometry, visual field examination and optic chsc analysis as previously 
validated (V emon 1998). 
Through the assistance of volunteer ophthalmologists, research fellows, orthoptlsts, nurses 
and medical students, large numbers of affected and unaffected members of extended 
families were examined. There were five masked examiners, each of whom assessed one 
parameter of glaucoma by following the standard clinical examination protocol for each 
patient (Appendix C); one member of the research team took a history, obtained consent, 
refracted and measured visual acuities; another examined visual fields; another measured 
IOP and performed gonioscopy; and two independent observers scored the optic discs, and 
finally fundus photographs and DNA via venepuncture were taken. 
Participants attended various eye clinics throughout Tasmania or were visited at their homes 
if unable to attend a clinic. A detailed questionnaire (Appendix D) and standard interview 
were administered covering knowledge of family history, demographic data, medications 
(including drug names and frequency of use), and medical history of systemic disorders such 
as hypertension, diabetes, migraine, corticosteroid use and systemic vascular disease. 
Problems with vision, past eye disease or eye treatment, and ocular symptoms were also 
included. For accuracy, patients were asked to bring all their medications or their physicians' 
medical summaries to the interview. 
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The detailed bilateral eye examination included subjective refraction and best-corrected 
visual acuity using the Snellen chart (Figure IV.1) . 
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Figure IV.1. Snellen chart. 
Seated IOP was taken using the standard calibrated Goldmann applanation tonometer (Haag 
Streit AG, Bern, Switzerland) with a drop of fluorescein 2.0% tear film (Chauvin 
Pharmaceuticals Ltd, Essex, UK) enhancement and local anesthetic on each eye 
(FigureIV.2) . The IOP was not standardised for time of day but the highest IOP record 
was used whenever possible to reduce the influence of diurnal variations. The IOP reading 
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was repeated if deemed unreliable. Attention was given to ensure the absence of tight 
clothing, particularly around the collar, as this could have potentially affected the venous 
pressure and influence IOP. This was followed by anterior segment examination with AC 
width assessed using the van Herick method (1969); any anterior chamber, iris, and lens 
abnormalities were recorded (FigureIV.3) . IOP from portable devices such as Perkins 
(Clement Clarke, Harlow Essex, UK) or Tonopen (Mentor, Norwell, MA, USA) were 
regarded as satisfactory if they were the only practical alternative (such as with the bed-
bound or in extreme geographical isolation). 
Figure IV.2. Slit lamp and Goldmann applanation tonometer 
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Figure IV. 3. Gonioprism for anterior chamber examination 
Optic disc analysis (FigureIV.4) was performed with pnor pupillary dilatation with 
tropicamide 1.0% and phenylephrine 10% (Chauvin Pharmaceuticals Ltd, Essex, UK) using 
both direct and indirect ophthalmoscopy, and a slit-lamp biomicroscope under magnifying 
binocular stereovision using a 78 or 90 dioptre noncontact lens or fundus contact lens . The 
following features were noted by two independent clinicians and were ranked according to 
the GIST scoring system (Appendix E): 
• Size of scleral canal (horizontal and vertical) 
• Presence and amount of peripapillary changes to retinal pigment epithelium and 
choroidal vasculature 
• Consistency and depth of retinal nerve fibre layer up to one disc distance from the disc 
edge 
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• Vascular branching pattern 
• Presence of 'Drance' type nerve fibre layer haemorrhages 
• Neuroretinal rim width, consistency and colour 
• Focal defects in the rim or pits not contiguous with the central cup 
• The vertical and horizontal cup-disc ratio as judged on contour (noting the phenomenon 
of 'overpass cupping'), 'bayonetting' of emerging nerve head vasculature, widening of the 
interstices of the lamina cribrosa, and posterior bowing of the lamina. 
Figure IV.4. Photographs of normal optic disc from study. 
Stereoscopic optic disc photographs were taken using a Nidek 3-Dx/F fundus camera 
(Nidek Co. Ltd, Japan) and Kodachrome ISO 64 film processed by Kodak (Eastman Kodak 
Co, Rochester, NY) (Figure IV.5). Each participant had bilateral 30 degrees color retinal 
stereophotographs taken centred on the optic disc and macula. 35 mm slide transparencies 
were mounted in clear plastic sheets, allowing close apposition of stereo pairs. 
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Figure IV.5. Fundus camera from study. 
Optic discs are measured from stereophotos using a Pentax stereoviewer II (Asahi Optical 
Co. Ltd, Japan). All optic discs or high-quality stereophotographs of the discs were scored 
independently by at least two glaucoma specialists based upon the GIST score protocol set 
out in Appendix E (Coote 1996). If there was a disagreement, a consensus between the 
ophthalmologists was reached. 
Visual field testing was performed with a standard Humphrey automated perimeter 
(Humphrey, Inc, San Leandro, CA) using a 24-2 array, a size III target, and full threshold test 
system (FigureIV.6). Both eyes were tested consecutively with a short break between each 
eye and using the appropriate near correction for 1 /3 metre. Testing was monitored by 
trained staff present in the room. Results were reviewed for reliability using fixation losses, 
false-positive errors, false-negative errors and short-term fluctuations, and defects were 
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detected using pattern deviation analysis (Figure IV. 7; FigureIV.8), with the criteria set out 
in Appendix E, as it standardises for overall decrease in contrast sensitivity which may 
occur secondary to cataracts (Coote 1996). 
Figure IV.6. Humphrey automated perimeter from study. 
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Figure IV. 7. Visual fields of an unaffected subject 
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Figure IV.8. Visual field pattern deviation analysis for calculation of GIST score. 
Iv.III Glaucoma Definition and GIST Score 
In this study, POAG was defined as an optic neuropathy with a GIST score of 0.7 or higher, 
with some or all of the following characteristics: 
• optic nerve head excavation with thinning of the neuroretinal rim, often with 'Drance' 
type nerve fibre layer haemorrhages, notching or pitting or significant focal or general 
l,oss of retinal fibre layer 
• elevation of IOP over a population-based normal or over the average of the unaffected 
individuals of the pedigree 
• visual field defects consistent with the disc changes and with common descriptions of 
glaucomatous field loss 
• no evidence of other forms of glaucoma, trauma, inflammation, pseudoexfoliation of the 
lens capsule, pigment dispersion, angle dysgenesis or other significant anterior segment 
pathology, or of potentially occludable angles on gonioscopy (Coote 1996; Damji 1999). 
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Individuals with a GIST score of 0.5 or lower constituted the 'control' group of unaffected 
subjects. Those with GIST score of 0.6 formed the 'borderline' group or glaucoma 
'suspects'. 
The GIST score was developed to give a probability score of glaucoma to family members as 
1t reflects objective physician grading of both patients and family members at the tlme of 
examination. 
In brief, it assigns a value to the findings of each of the 3 standard tests described above. 
There are possible 2 points for glaucomatous disc changes, 1 point for elevated IOP and 1 
point for visual field changes consistent with glaucoma. These summate to a 'raw score', 
which is then translated into the pedigree probability or the GIST score (includes a 
component of probability of unaffected status) as it increases at intervals of 0.1 by each 'raw 
score' point to a maximum of one. This GIST score is a numerical value between zero and 
one starting at 0.5, where zero or 0.1 is clinical certainty of absence of disease and 0.9 or one 
is the definitive diagnosis of POAG (the full methodology and variations of the GIST 
scoring system are described in the Reference). 
Therefore, to a limited extent, the GIST score correlates positively with the severity level of 
glaucoma in a given individual. 
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The GIST score excludes those who are normal at examination but are too young to exclude 
the disease and those with glaucoma that is considered to be highly distinct from the 
pedigree phenotype. For example, if the 'raw score' is zero, the GIST score is decreased by 
units of 0.1 depending on age of the individual and the average age of onset of the disease in 
that pedigree (Coote, 1996). 
The GIST score is developed for the individual, and the eye with the highest raw score is 
used in the calculation. This pedigree probability is not a true probability, which would also 
need to account for the random occurrence of glaucoma (approzjmately 3% in Australia) 
(Mitchell 1996) as well as the reduced probability of second- and third-degree relatives being 
affected. The GIST score is designed so that patients are given a probability score, rather 
than included or excluded based on the presence of a single feature. For example, it is 
possi.ble for an individual to have a GIST score of 0.9 in the absence of elevated IOP. 
For 'triangulation', the accuracy of individuals' recall of their family history of glaucoma in 
questionnaire and at interview was assessed by comparing to the genealogic data and by 
using the standard GIST score system, which resulted in 84 subjects being reallocated from 
the familial group to the sporadic group as they had no other affected relatives on 
examination. 
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DNA was tested using standard protocol at University of Iowa, USA (Dickinson, 2001), 
where mutations of the GLC1A gene was ascertained by single-strand conformation 
polymorphism (SSCP) analysis and subsequent direct sequencing. 
IV.IV Data Management & Statistical Analysis 
All data were entered into a password-verified Microsoft Access database, using automatic 
skips and range checks. Microsoft Excel was used for tabulations and graphics. Statistical 
analyses, including chi-square test and multiple logistic regression analyses, were performed 
using the SPSS statistical package version 10 (SPSS Inc., Chicago, USA). For every subject in 
the study, data were provided on the following variables: 
Group Control, Familial Glaucoma, Sporadic Glaucoma. 
GIST Score Treated as scaled vanable m compansons of Familial and Sporadic groups. 
Degree of Relatives Levels of genetic connection to glaucoma sufferers (Familial group only) 
Pedigree Genetically related groups 
Age Approxunate age m years (Given the study runs over a 4 years period, the best approximation to age is provided by the 
number of years from date of birth to rmddle point of data collection period 
Gender Female, male. 
IOPmax maximum mtraocular pressure. 
Risk variables Hypertension, smoking, diabetes, transfusion, atherosclerosis, cold extrermtles, thyroid, rmgraine, stenods all binary 
variables with categones TREU/FALSE 
Table IV.2- Variables in the study and their descriptions. 
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The size of familial glaucoma pedigree groups varied from 2 to 29. There were three groups 
containing 20-29 members, three groups containing 10-19 members, and 301 groups with 
fewer than 10 members. Within pedigree comparisons versus sporadic group was confined 
to the three groups with at least 20 members. Presuming that pedigree groups are imprecise 
indicators of individual genes or gene groups that may have an association with glaucoma, it 
was decided that a fruitful path to follow, if practical, would be classification based on genes 
or genetic groups. 
The data were stratified by GIST scores in the familial and sporadic glaucoma groups, and 
by closest degrees of relatives with POAG in the familial glaucoma group. First-degree 
relatives are father, mother, son, daughter, and siblings. Second-degree relatives are 
grandparents, grandson, granddaughter, aunt, uncle, nephew and niece. Third-degree 
relatives are first cousins, great-grandparents, great aunt/uncle, great-grandson, great-
granddaughter. Fourth-degre~ relatives are more distant relatives, including second cousins' 
children and great-great-grandparents. 
"Degree" of relationship to known glaucoma sufferers was identified on a four level 
categorisation. The distribution of familial subjects among the four degree classes is as 
follows: 
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Table IV.3 - Distribution of degree of relatives in the familial glaucoma group. 
1 2 3 4 
65% 9% 9% 16% 
IV.V Statistical Methods 
Logistic regression analysis was employed to compare odds for risk factors between the 
familial and sporadic groups and then adjusted for differences in supplementary variables -
age and gender - as appropriate. Where sample sizes were sufficiently large, separate analyses 
were performed within pedigree groups. Interaction between GIST score and risk factors 
was included in some analyses to determine if differences between familial and sporadic 
groups were consistent across different severity levels of glaucoma. The "degree" variable 
was transformed into a binary variable to allow comparison of degree 1 versus the rest or 
degrees 1 and 2 versus degrees 3 and 4, and included in an interaction term with risk factors 
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to establish if differences in odds between the familial and sporadic for any risk factors 
varied with degree of genetic connection to known glaucoma sufferers. Stepwise logistic 
regression analysis was employed to determine relations that may exist amongst the risk 
factors in so far as they affect POAG. Odds ratio estimates are accompanied by 95% 
confidence limits. 
The sampling procedure employed also allowed another perspective to be examined, namely 
to consider risk factors as response variables. This approach was used to plot odds of 
true/ false in risk variables versus GIST score with separate plots for familial and sporadic 
groups. It was a useful tool to highlight differences between the familial and sporadic groups 
where the above analyses indicate significant differences occur. 
For each individual risk factor, a log-linear model was fitted and a Likelihood ratlo test 
employed to establish if there were differences in odds among the three populations -
control, familial glaucoma, and sporadic glaucoma. 
Poisson regression analysis was used to test for the hypothesis of an inverse relationship 
between decreasing number or proportion of subjects in either the familial or sporadic 
glaucoma group and increasing GIST scores over time. 
To determine if the distribution of GIST scores differed between the familial and sporadic 
groups, the two-tailed Kolmogorov-Smirnov test was employed (this test is preferred to 
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the Mann-Whitney test because it is sensitive to any type of difference, including two 
frequency distributions). 
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CHAPTERV 
RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
FAMILIAL AND SPORADIC GLAUCOMA GROUPS 
CHARACTERISTICS 
''Data isn't information, information isn't knowledge and knowledge isn't wisdom" 
(Anon) 
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V.I Group Characteristics 
Number of Subjects 
Ignoring the borderline or glaucoma 'suspect' group with GIST scores of 0.6 (n=486), 2444 
subjects were divided into three groups: familial glaucoma (n=1014), sporadic glaucoma 
(n=688) and unaffected group (n=742) (Figure V.1). 
Figure V.1 - Comparison of Number of 
Subjects in each Group. 
Gender 
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The distribution of gender in each group was similar (Figure V.2). There is no significant 
difference in gender distribution in the familial glaucoma group compared to the sporadic 
glaucoma group (OR 1.053; 95% Cl 0.819-1.353). 
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Figure V.2 - Comparison of the 
Distribution of Gender in each Group. 
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GIST Scores 
The percentage of patients in each GIST score group tends to decline with increasing GIST 
scores in a non-linear fashion in both the familial (p<0.001) and sporadic (p<0.001) 
glaucoma groups (Figures V.3 & V.4), suggesting a greater percentage of POAG subjects in 
the lower end of the 'severity' spectrum. 
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Figure V .3 - Distribution of GIST Scores in the 
Familial Glaucoma Group. 
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Figure V.4 - Distribution of GIST Scores in the 
Sporadic Glaucoma Group. 
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Table V.1 highlights that the large majority (96%) of people in the unaffected group had 
unchanged GIST scores of 0.5, with the remaining 4% representing those who were 
expected to have lower GIST scores. The familial glaucoma group has a greater proportlon 
of subjects with a GIST score of 0.9 (p=0.004) or 1.0 (p<0.001) compared to the sporadic 
glaucoma group. 
Table V.1 - Distribution of the GIST Scores in the familial glaucoma, sporadic 
glaucoma and unaffected groups. 
Number GIST 
(%) Scores 
Group 0 0.5 0.7 0.8 0.9 1 Total 
Unaffected 28 (4%) 714 (96%) 742 (100%) 
Familial 345 (34%) 282 (28%) 193 (19%) 194 (19%) 1014(100%) 
Sporadic 296 (43%) 221 (32%) 96 (14%) 75 (11%) 688 (100%) 
Total 28 714 641 503 289 269 2444 
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There is evidence that the distribution of GIST scores differ between the two glaucoma 
populations. 
The familial glaucoma group is more represented in the higher GIST score levels and the 
sporadic glaucoma group has a higher prevalence in the lower GIST score levels. 38.2% of 
the familial glaucoma group compared to 24.9% of the sporadic glaucoma group has a GIST 
score of 0.9 or 1.0 (p<0.005). 
The cumulative graph of GIST scores (Figure V.5) highlights the discrepancy in its 
distribution within the familial glaucoma group compared to the sporadic glaucoma group, 
which is highly statistically significant in the 2-tailed Kolmogorov-Smirnov test (p<0.001). 
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Figure V.5 - Cumulative Graph of GIST Scores in 
Familial and Sporadic Glaucomas 
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Degree of Relatives 
Table V.2 - Distribution of the closest degree of relatives affected with POAG in the 
familial glaucoma and sporadic glaucoma groups. 
Number Degree of 
(%) Relatives 
Group 1 2 3 4 Unrelated Total 
Unaffected 742 (100%) 742 
Familial 658 (65%) 110 (11%) 103 ( 10%) 143 (14%) 1014 
Sporadic 688 (100%) 688 
Total 658 110 103 143 1430 2444 
Table V.2 illustrates that in the familial glaucoma group, nearly two-thirds of people had a 
first-degree relative also affected with POAG. Nearly a sixth of the familial glaucoma group 
had a fourth-degree or more distant relative also affected with POAG. Approximately 10% 
each had a second- or third-degree affected relative (Figure V.6). 
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By definition, no-one in the sporadic glaucoma group had an affected relative. 
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Figure V.6 - Distribution of closest Degree of 
Relatives affected with POAG in the Familial 
Glaucoma Group. 
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V.Il Potential Confoun ding E ffect of Age and Gender 
Possible relationships among supplementary variables such as age and gender may exist and 
are presumed to be important in explaining odds of a person having glaucoma and for which 
adjustment is required in the examination of relationships with potential risk factors. Figure 
V.7 illustrates the median age and standard deviation in each group, which appeared to be 
similar between familial and sporadic glaucoma. Both groups consisted of older individuals 
compared to the unaffected group with GIST score of 0.5 or less (median age for females 
and males was 54 and 53 years, respectively). 
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Figure V.7 - Graph of Average Age and 
Standard Deviation in each Group. 
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Table V.3 - Median age of males and females in familial glaucoma, sporadic 
glaucoma and unaffected groups. 
Median Age (Year) Gender 
Group F M 
Unaffected 54 53 
Familial 71 69 
Sporadic 73 71 
Grand Total 66 65 
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The situation becomes clearer when the age difference between the groups are broken down 
by GIST scores: 
Table V.4 - Median age in familial glaucoma, sporadic glaucoma and unaffected 
groups at different GIST scores. 
Median Age (Year) GIST 
Score 
Group 0 0.5 0.7 0.8 0.9 1 Total 
Unaffected 55 53 53 
Familial 65 71 72 74 70 
Sporadic 71 73 74 74 72 
Total 55 53 68 72 73 74 66 
It can be seen that the aberrant group is the familial group with GIST levels of 0.7. Breaking 
the figures in the above cells into female and male components (not shown), there is very 
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little gender imbalance except in the familial group with GIST score of 0.7, where 1t is found 
that the median female age is 66 and the median male age is 64. For all other cells the 
median age for females and males ranges between 71 and 75 years. 
The influence of age on the relative odds for the familial and sporadic groups is seen in the 
following test results in which age is the single explanatory variable in the model: 
Table V.5 - Comparison of odds ratio and confidence intervals with age as a single 
explanatory variable. 
GIST scores included p-value odds ratio 95% confidence interval 
0.7 to 1.0 <0.001 1.016 1.008 - 1.024 
0.8to1.0 0.14 1.008 0.997 -1.019 
There is no significant difference between familial and sporadic glaucoma groups based on 
subjects with GIST scores of 0.8 or higher (OR 1.002; 95%CI 0.991-1.013). 
For gender there is not a significant difference. 
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V.111 Comparisons within pedigree groups 
1
Table V.6 shows the distribution of 87 subjects in pedigree GTas01, the second largest 
pedigree in the study. 
Table V.6 - Distribution of subjects by gender and GIST scores in the GTasOl 
pedigree. 
Number GIST 
SCORE 
Group Gender 0 0.5 0.7 0.8 0.9 1.0 Total 
Unaffected F 1 34 35 
M 27 27 
Unaffected 1 61 62 
Total 
Familial F 8 3 3 14 
M 3 6 1 1 11 
Familial 11 9 1 4 25 
Total 
Total 1 ' 61 11 9 1 4 87 
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These numbers are too small to allow separation of effects of risk factors from GIST scores. 
Using GTas02 as an example below, the same situation applies with other pedigree groups 
which have smaller number of family members. 
If the members with GIST = 0.7 or greater are included there are only 20 members of 
GTas02. 
Table V.7 - Distribution of subjects with GIST score 0.7 or greater in GTas02 
pedigree. 
Group Number(%) 
Familial GTas02 20 (2.8%) 
Sporadic 688 (97 2%) 
Total 708 (100%) 
If the restriction is for GIST of 0.8 or greater there are only 13 members in GTas02. 
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Table V.8 - Distribution of subjects with GIST score 0.8 or greater in GTas02 
pedigree. 
Group Number(%) 
Familial GTas02 13 (3.2%) 
Sporadic 392 (96.8%) 
Total 405 (100%) 
Indeed, the numbers are too small for meaningful analysis, given that the 13 subjects in 
GTas02 have to be split between the two levels (true/false) of a risk factor. 
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V.IV Comparing Odds for Familial versus Sporadic Glaucoma Groups 
Table V.9 and Figure V.8 summarises the unadjusted odds ratios (familial versus sporadic 
glaucoma) and 95% confidence intervals for various risk factors. 
Table V.9 - Unadjusted odds ratios and 95% confidence intervals for various risk 
factors present in familial glaucoma versus sporadic glaucoma groups. 
Risk factor p-value odds ratio 95% confidence interval 
Hypertension 0.19 0.838 0.643 - 1.092 
Smoking 0.19 0.752 0.491 - 1.152 
Diabetes 0.5 1.138 0.767 - 1.688 
Transfusion 0.96 0.992 0.726 -1.355 
Atherosclerosis 0.03 0.699 0.505 - 0.967 
Cold extremities 0.5 0.920 0.709 - 1.201 
Thyroid 0.7 0.916 0.607 - 1.382 
Migraine 0.5 0.879 0.599 - 1.291 
Steroids 0.75 1.045 0.799 - 1.366 
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_, 
Only" atherosclerosis (P=0.03) was found to be significant in the unadjusted odds ratios. 
In stepwise fitting employing all risk factors, no risk factor is retained in the final equation 
(these results are elaborated in chapters VI-XVI). 
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Figure V.8 - Graph of Unadjusted 
Odds Ratio for various Risk Factors. 
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DISCUSSION 
Age and Gender 
1. Comparisons between familial and sporadic groups should be restricted to suijects with GIST scores 
greater than 0. 7 if confaunding effects of age and gender are to be minimised. 
2. AJry comparisons between the familial or sporadic groups and control group will be coefounded with both 
age and gender. 
The following assumptions have been made in the study: 
1. the relative proportions provide unbiased estimates of the distribution of the Tasmanian 
population who have GIST scores greater than or equal to 0.5 among the three 
subpopulations; and 
2. the samples from the three populations can be treated as though they are randomly 
selected from the respective populations, although many of the unaffected are relatives 
of the affected participants. 
In this study, nearly 60% of all glaucoma subjects were objectively classified into the familial 
group (1014/1702 or 59.6%), giving support to previous studies which reported that over 
50% of all people with POAG in the community have a positive family history of glaucoma 
(McNaught 2000). 
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This investigation also found that the distribution of gender between the familial and 
sporadic glaucoma groups was similar and not statistically significant (OR 1.053; 95% Cl 
0.819-1.353), reflecting the autosomal rather than sex-linked inheritance of familial POAG. 
In contrast, there were a greater proportion of females (43.1%) in the total glaucoma group 
compared to that in the unaffected 'control' group (40.7%), but the difference was not 
statistically significant (OR 1.102; 95% Cl 0.925 -1.313). 
This .supports the Blue Mountains Eye Study, which found a higher prevalence of POAG in 
Australian women in comparison to men (OR 1.5; 95%CI 1.0-2.2)(Mitchell 1996). The 
discrepancy in magnitude of gender difference may reflect true differences in the two study 
populations or may reflect a chance variation. In contrast, the Melbourne Visual 
Impairment Project found no relationship between POAG and gender (Wensor 1998). 
Notably, there was a higher rate in white men in some studies (Leibowitz 1980; Leske 1996), 
but not in others (Mason 1989; Tielsch 1991; Leske 1983; Kahn 1980; Hollows 1966; I<J.ein 
1991; Alward 2000). Indeed, population-based studies have yielded conflicting results on 
sex-specific glaucoma prevalence. 
In both the familial (p<0.001) and sporadic (p<0.001) glaucoma groups, the proportion of 
subjects in each GIST score group tends to decline in a non-linear fashion with increasing 
GIST scores This may reflect the co-morbidities associated with more severe glaucoma 
types. It may also simply reflect the age-glaucoma relationship, whereby glaucoma becomes 
more prevalent and severe with increasing age, as do other medical illnesses that are 
associated with higher mortality, such as coronary artery disease and cancer. 
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In the Rotterdam eye study, siblings of patients with POAG (familial POAG) were on 
average 3 years younger than siblings of people with no glaucoma and had significantly 
higher IOP and cup-to-chsc ratios (Wolfs 1998). In this study, the distribution of GIST 
scores (probability scores of glaucoma based on IOP, optic disc and visual field changes) 
tended to be skewed towards higher range of scores in the familial glaucoma group 
compared to the sporadic glaucoma group (p<0.001), which may reflect an earlier onset 
and/ or higher severity of glaucoma in the familial group. Indeed, familial POAG pedigrees 
with the Gln368STOP mutation in the myocilin gene is of a younger age of onset, has a 
higher peak IOP and is more likely to have undergone glaucoma drainage surgery compared 
to non-mutation glaucoma cases (Craig 2001). Furthermore, some of the other mutations 
found in the myocilin gene, such as Thr377met, Tyr437His and lle477Asn, have an even 
younger average age of onset, higher peak IOP and is more likely to have undergone 
glaucoma drainage surgery (Mackey in-press, Alward 1998). 
Further elaboration is required to investigate the hypothesis of an earlier onset and/ or higher 
severity of glaucoma in the familial group .. 
The small number of subjects within each pedigree precludes valid statistical comparisons of 
odds. of clinical risk factors in each pedigree of familial glaucoma versus the sporadic 
glaucoma group. The most useful approach in relation to pedigree groups would seem to be 
a search for indicator genes that would allow combination of pedigrees with a common 
gene, so that sample numbers are built to a stage where reliable analysis is possible and the 
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separation of possible genetic effects from age and severity is possible. This will be discussed 
further in chapter VI. 
It is thus clear that both age and gender are important potential confounders and should be 
adjusted for in our study comparing the prevalence of various risk factors between the 
familial and sporadic glaucoma groups. 
Clinical Risk Factors 
The preliminary unadjusted odds ratios suggest that atherosclerosis is significantly less 
prevalent in the familial glaucoma group compared to the sporadic glaucoma group. 
However, after stepwise fitting of all risk factors, it is not retained in the final equation, 
indicating that the effect of atherosclerosis may be exerted by a third factor such as 
hypertension. These relationships will be examined in detail in chapters VI-XI. 
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CHAPTER VI 
RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
HYPERTENSION 
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RESULTS 
Analysis was undertaken from two perspectives: firstly, how the odds of a subject having 
hypertension differed between the familial and sporadic groups and secondly, how the odds 
of having hypertension differed as the GIST score changed. Finally, there was a test to 
determine whether the relationship between the odds of having hypertension versus GIST 
score varied between the familial and sporadic groups. 
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VI.I Familial versus Sporadic Glaucoma Comparison 
The following results in Table VI.1 apply when the analysis is restricted to subjects with 
GIST scores greater than 0.7. 
Table VI.1 - Unadjusted and adjusted odds ratios and confidence intervals of 
hypertension in familial glaucoma group compared to sporadic glaucoma group. 
Adjustment p-value odds ratio 95% confidence interval 
None 0.19 0.84 0.64-1.09 
All other rtsk factors 0.28 0.86 0.65-1.13 
GIST Score 0.16 0.82 0.63-1.08 . 
-
Age and gender 0.17 0.83 0.63-1.08 
Initial analysis showed that the prevalence of hypertension is not statistically significant in 
the familial glaucoma group compared to the sporadic glaucoma group (unadjusted OR 0.84; 
95%CI 0.64-1.09). 
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The difference is unchanged after adjusting for all other risk factors (diabetes, smoking, 
migraine, atherosclerosis, steroids, transfusion, cold extremities and thyroid disorders) (OR 
0.86; 95%CI 0.65-1.13), or age and gender (OR 0.83; 95%CI 0.63-1.08). 
VI.II Relationship of Odds of having Hypertension versus GIST Score 
As shown in table VI.1, the odds of hypertension (familial versus sporadic glaucoma) 
strengthened marginally but were not significant after adjusting for GIST scores (OR 0.82; 
95%CI 0.63-1.08). 
The distribution of subjects across GIST scores is summarised in table Vl.2 below. 
Table VI.2 - Distribution of hypertension versus no hypertension and odds of 
hypertension as a function of GIST scores in the familial glaucoma, sporadic 
glaucoma and unaffected groups. 
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Number GIST 
Score 
HYPERTENSION Group 0 0.5 0.7 0.8 0.9 1 Total 
FALSE Unaffected 20 551 571 
Familial 211 181 123 127 642 
Sporadic 182 143 74 51 450 
FALSE Total 20 551 393 324 197 178 1663 
TRUE Unaffected 8 163 171 
Familial 134 101 70 67 372 
Sporadic 114 78 22 24 238 
TRUE Total 8 163 248 179 92 91 781 
Grand Total 28 714 641 503 289 269 2444 
There is a greater number of people with no hypertension compared to people with 
hypertension across all GIST scores in all 3 groups. A total of 238 out of 688 (34.6%) in the 
sporadic glaucoma group has hypertension, while a total of 372 out of 1014 (36.7%) in the 
familj.al glaucoma group has hypertension (Table VI.2). Overall, a total of 610 glaucoma 
patients out of 1702 (35.8%) have hypertension. 
Figure VI.1 below plots the odds of a subject having hypertension as a function of GIST 
score. Separate plots are shown for the familial and sporadic groups and the average of the 
two groups. Please note that the value provided at a GIST score of 0.5 is obtained from the 
unaffected group. 
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Figure VI - Comparison of odds of hypertension in familial glaucoma, sporadic 
glaucoma and unaffected groups 
It can be seen in Figure VI above, there is a significant difference in odds for familial and 
sporadic groups when the GIST score is 0.8 or greater and that the observed difference cannot 
be explained as an age or a gender effect. It appears that the odds of hypertension remains 
constant in the familial group, but reduces in the sporadic group in the range from 0.8 to 1.0. 
It should be noted that the comparison at GIST =0.7 is confou,nded by age and gender 
(chapter V). 
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VI.III Relationship of Odds of Hypertension versus Gender 
Table VI.3 shows the number of males and females with and without hypertension mall 
three groups. 
Table VI.3 - Distribution of hypertension versus no hypertension in males and 
females in familial glaucoma, sporadic glaucoma and unaffected groups. 
Count of Type Gender 
HYPERTENSION Type F M Total 
TRUE Control 117 54 171 
Familial 240 132 372 
Sporadic 154 84 238 
TRUE Total 511 270 781 
FALSE Control 323 248 571 
Familial 341 301 642 
'Sporadic 234 216 450 
FALSE Total 898 765 1663 
Grand Total 1409 1035 2444 
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In the familial glaucoma group, hypertension was found in 240 out of 581 females (41.3%) 
and in 132 out of 433 males (30.5%). In the sporadic glaucoma group, hypertension was 
found in 154 out of 388 females (39.7%) and in 84 out of 300 males (28.0%). These 
differences were not statistically significant (OR 1.01; 95% Cl 0.72 - 1.40). Nonetheless, 
adjusting for age ·and gender marginally improved the significance of the hypertension 
I 
difference between familial and sporadic glaucoma groups from odds ratio of 0.84 to 0.83. 
VI.IV Relationship to Degree of Relatives 
Restricting the familial group dependent on degree of relationship produced the following 
- -
results in comparison of the familial and sporadic groups using subjects with GIST scores of 
0.8 or higher: 
Table VI.4 - Odds of hypertension by degree of relatives of familial glaucoma group 
compared to the sporadic glaucoma group. 
Degree of Relative p-value odds ratio 95% confidence intervals 
1 SI 0.555 0.916 0.684 - 1.227 
2nd 0.229 0.727 0.4~3 - 1.222 
3rd 0.324 0.765 0.450 - 1.302 
4th 0.099 0.683 0.433 -1.075 
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There is no statistically significant difference in odds of hypertension between the familial 
glaucoma degree of relatives subgroups and sporadic glaucoma, suggesting the absence of 
any difference overall. 
VI.V - Relationship to Mutations in GLCJA Gene 
Table VI.5 summarises the prevalence of hypertension and no hypertension in the fainilial 
glaucoma GTas02 pedigree as a function of laboratory-identified Gln368STOP mutation in 
the GLC1A gene. 
Table VI.5 - 2x2 table comparing the prevalence of hypertension and GLC1A gene 
Gln608STOP mutation in the familial glaucoma GTas02 pedigree. 
Hypertension GLC1A mutation 
Yes No Total 
Yes 7 12 19 
No 36 92 128 
TOTAL 43 104 147 
# 
Note -There were an extra 8 cases where the gene test results are ambiguous and hence were excluded from 
the above figures. 
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Application of the Chi-squared test to the above data yielded a p-value of 0.4, which suggests 
that the observed difference in the ratio of hypertension to no hypertension cases between 
the GLC1A gene mutation ar:d no mutation groups could reasonably be explained as a 
chance variation. 
DISCUSSION 
There appears to be no statistically significant difference in the odds of hypertension 
between the familial and sporadic glaucoma groups in subjects with GIST scores of 0.8 or 
greater after adjusting for other clinical factors (OR 0.86; 95%CI 0.65-1.13), and differences 
in age and gender (OR 0.83; 95%CI 0.63-1.08) or GIST scores (OR 0.82; 95%CI 0.63-1.08). 
Moreover, there is no statistically significant difference in odds of hypertension between 
degree of relatives subgroups in familial glaucoma and sporadic glaucoma. 
An extension of the study was undertaken to examine the relationship between the r~tio of 
hypertension to non-hypertension cases and presence or absence of known mutations in the 
GLC1A gene. This gene was identified by standard laboratory tests with single-strand 
conformation polymorphism (SSCP) analysis and subsequent direct sequencing (Dicksinson 
2001) in a specific pedigree, namely GTas02. A chi-square probability of 0.4 suggests that the 
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difference observed was not statistically significant and was likely to be due to chance. By 
extrapolation, this implies that there is unlikely to be any statistically significant difference in 
the prevalence of hypertension between familial and sporadic glaucoma groups. 
Indeed, it is likely that hypertension is a multi.factorial disorder, with varying degrees of 
genetic predisposition, and modified by a multitude of environmental/lifestyle factors such 
as obesity and level of physical activity. A direct association between hypertension and 
familial POAG would seem to be too simplistic. 
The possible role of systemic vascular factors in POAG pathogenesis has been debated for 
many years (Phelps 1972; Drance 1973). Hypertension could increase POAG risk indirectly, 
through its association with lugh IOP (Leske 1983; Hiller 1982; Bulpitt 1975; Bengtsson 
1972; I<Jein 1981), or may increase POAG risk directly through small-vessel disease. That is, 
ocular capillary and small vessels circulation may be more precarious as blood pressure 
increases, and impaired perfusion pressure in vessels supplying the optic disc may contribute 
to glaucoma (Ellenberg 1979). Local vascular factors such as myogenic tone may also play a 
role (Wilson 1999). 
On the other hand, hypertension might 'protect' against POAG by providing an adequate 
perfusion pressure, which has led to concern that antihypertensive treatment may increase 
risk of field loss (Phelps 1972; Weinstock 1973). However, this premise is not supported by 
findings in the Long Island Study (Leske 1996). 
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Paradoxically, a decrease in blood pressure (relative to IOP), such as in hypotensive crisis, 
mcreases glaucoma risk (Drance 1973). This occurrence of glaucomatous damage despite 
normal or low pressures, supports the view of glaucoma as two separate diseases (lngh-
tension and low-tension glaucoma) with different pathophysiology. A role has been 
hypothesised for antihypertensive treatment, hypotensive episodes, or any vascular-related 
factor that could affect the blood pressure-IOP relationship needed for optic disc perfusion 
(Leske 1983; Kahn 1980). 
Results from population-based studies have differed. In the Baltimore Eye Survey, there was 
no significant association between hypertension and POAG. Race-adjusted odds ratios 
tended to be lower at younger ages and higher at older ages, suggesting that hypertension is 
protective at ages under 60 and damaging at older ages (Tielsch 1995). However, the results 
were not statistically significant. 
In the smaller Rotterdam POAG study (n=42), a positive relationship between hypertension 
and POAG was found only in cases with high IOP; however the odds ratio was not 
significant (Dielemans 1995). Furthermore, the Barbados Eye Study (n=302 definite cases of 
POAG) found that an elevated systolic blood pressure, regardless of treatment, was 
associated with POAG at ages under 70 years; however the association was weak and did not 
persist after age-sex adjustment or multivariate analysis (Leske 1995). More recently, the 
Long Island Study also did not support the hypothesis that systemic hypertension 
independently increases the risk of POAG field defect (Leske 1996). 
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It is of interest to note that both the Barbados Eye Study and the Long Island study found a 
significant association between POAG and low perfusion pressure ~ow diastolic blood 
pressure-IOP differences). An association between low systolic and diastolic blood pressure 
to IOP ratios has also been documented (Leske 1995; Leske 1996) but not examined in the 
present study. The role of vascular risk factors is consistent with findings of low blood 
pressure to IOP ratios, but this could be explained by the high IOP in POAG rather than by 
a relatively low blood pressure. Moreover, the relationship between systemic blood pressure 
and IOP may not accurately reflect the local perfusion pressure at the optic disc. 
At present, therefore, there is insufficient evidence to support the role of hypertension as a 
strong independent risk factor for POAG or its familial subgroup. 
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CHAPTER VII 
RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
DIABETES MELLITUS 
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RESULTS 
Analysis was undertaken from two perspectives: firstly, how the odds of a subject being a 
diabetic differed between the familial and sporadic groups and secondly, how the odds of 
having diabetes changed as the GIST score changed. Finally, there was a test to determine 
whether the relationship between the odds of having diabetes versus GIST score varied 
between the familial and sporadic groups. 
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VII.I Familial versus Sporadic Glaucoma Comparison 
Table VII.1- Unadjusted and adjusted odds ratios and 95% confidence intervals of diabetes 
mellitus in familial glaucoma group compared to sporadic glaucoma group. 
Adjustment p-value odds ratio 95% confidence interval 
None 0.5 1.14 0.77 -1.69 
Other risk factors 0.3 1.22 0.81-1.83 
GIST Score 0.7 1.09 0.73 -1.62 
Age and gender 0.5 1.14 0.77 -1.70 
Table VII.1 records the p-value, odds ratio plus 95% confidence limits for the unadjusted 
and adjusted situations: there is no evidence of differences in odds of diabetes between 
familial and sporadic groups. 
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VII.II Relationship of odds of Diabetes versus GIST score 
The distribution of subjects across GIST scores is summarised in table VII.2. 
Table VII.2 - Distribution of diabetes versus no diabetes and odds of diabetes as a 
function of GIST scores in the familial glaucoma, sporadic glaucoma and unaffected 
groups. 
Number GIST 
Score 
DIABETES Group 0 0.5 0.7 0.8 0.9 1 Total 
FALSE Unaffected 24 694 718 
Familial 309 253 163 183 908 
Sporadic 258 192 86 68 604 
FALSE 24 694 567 445 249 251 2230 
Total 
TRUE Unaffected 4 20 24 
Familial 36 29 30 11 106 
Sporadic 38 29 10 7 84 
TRUE 4 20 74 58 40 18 214 
Total 
Grand Total 28 714 641 503 289 269 2444 
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There was a greater number of people with no diabetes compared to people with diabetes 
across all GIST scores in all three groups. A total of 76 out of 688 (11.0%) in the sporadic 
glaucoma group had diabetes, while a total of 160 out of 1014 (15.8%) in the familial 
glaucoma group had diabetes (Table VIl.2). Overall, a total of 236 glaucoma patients out of 
1702 (13.9%) had diabetes. A test of the hypothesis that the odds of a person having 
diabetes is the same for the familial and sporadic glaucoma groups is not rejected after 
adjusting for GIST scores (OR 1.09; 95% Cl 0.73-1.62). 
Figure VII.1 below plots the odds of a subject having diabetes as a function of GIST score. 
Separate plots are shown for the familial and sporadic groups and their averages. However, 
the difference in patterns was not statistically significant. Note that the value provided at a 
GIST score of 0.5 was obtained from the unaffected 'controls' group. 
Pairwise comparisons established that the odds of diabetes at GIST score of 0.5 and 1 were 
not statistically significant between the two glaucoma populations. 
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Figure VII - Comparison of odds of diabetes in familial glaucoma, sporadic 
glaucoma and unaffected groups. 
VII.III - Relationship of Odds of Diabetes versus Gender 
Table VIl.3 shows the number of males and females with and without diabetes in all 
three groups. 
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Table VII.3 - Distribution of diabetes versus no diabetes in males and females in 
familial glaucoma, sporadic glaucoma and unaffected groups. 
Count of Type Gender 
DIABETES Type F M Total 
TRUE Control 14 10 24 
Familial 56 50 106 
Sporadic 47 37 84 
TRUE Total 117 97 214 
FALSE Control 426 292 718 
Familial 525 383 908 
Sporadic 341 263 604 
FALSE Total 1292 938 2230 
Grand Total 1409 1035 2444 
In the familial glaucoma group, diabetes mellitus was found in 56 out of 581 females (9.6%) 
and in 50 out of 433 males (11.5%). In the sporadic glaucoma group, diabetes was found in 
47 out of 388 females (12.1 %) and in 37 out of 300 males (12.3%). The differences were not 
statistically significant (OR 1.13; 95%CI 0.64-2.1). The odds of diabetes between familial and 
sporadic glaucoma groups remained non-significant after adjusting for gender and age (OR 
1.14;·95%CI 0.77-1.70). 
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VII.IV - Relationship to Degree of Relatives 
Table VII.4 - Odds of diabetes in subgroups of familial glaucoma versus sporadic 
glaucoma group as a function of degrees of relatives affected with POAG. 
Degree of Relative p-value odds ratio 95% confidence intervals 
1st 0.369 1.225 0.787 - 1.907 
2nd 0.879 1.064 0.479 - 2.359 
3rd 0.519 0.784 0.375 -1.640 
4th 0.648 1183 0.575 - 2.437 
As shown in Table VII.4, subgroups of degrees of relatives in the familial glaucoma group 
demonstrate no significant difference in odds of diabetes between the familial and sporadic 
glaucoma groups. 
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DISCUSSION 
The prevalence of diabetes amongst individuals with POAG in this study was 13.9%, slightly 
more than that reported in the Blue Mountains Eye Study (12.5%) (Mitchell 1997). This may 
be because diabetes was ascertained by questionnaire and by use of antidiabetic medications 
in this study. The use of biochemical evidence of abnormal glucose tolerance might have 
detected undiagnosed diabetes in the community and reveal a higher difference. 
The lack of significant association between familial glaucoma and diabetes (OR 1.14; 95%CI 
0.77-1.69) persisted after adjusting for age and gender (OR 1.14; 95%CI 0.77-1.70), another 
potential risk factors (OR 1.22; 95%CI 0.81-1.83). This may be due to the fact that the 
majority of diabetes is non-insulin dependent adult-onset diabetes, which increases with age 
and environmental factors such as obesity. It would probably have the same influence on 
both the familial and sporadic glaucoma groups. This finding also supports the conclusion 
from the Blue Mountains Eye Study, which reported no change in the diabetes-glaucoma 
relation after adjusting for family history of glaucoma (Mitchell 1997). 
Similarly, no significant association was found in the distribution of diabetes between the 
familial and sporadic glaucoma groups as a function of GIST scores or degree of relatives. 
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A number of hypotheses on the pathogenesis of an association between diabetes and 
glaucoma have been proposed. The increased prevalence of glaucoma may reflect optic 
nerve damage as a result of vascular or other effects of diabetes (Becker, 1971), such as those 
on the small vessels of the eye (Wilson 1999). The reported IOP rises could be a 
manifestation of the systemic autonomic dysfunction observed in diabetes (Armstrong 1960; 
Mapstone 1985). This may provide the mechanism for association not only between diabetes 
and glaucoma, but also between diabetes and elevated IOP reported in some studies (Tielsch 
1995; Leske 1983; Jain 1967; Mitchell 1997) but not in others (Bouzas 1971; Seddon 1983). 
Moreover, a direct osmotic effect of hyperglycaemia might be expected to lower rather than 
increase IOP (Dielemans, 1994). 
Therefore, at present, there is no strong evidence for an association between familial POAG 
and diabetes mellitus. However, if there is an association between diabetes and POAG, it 
may in part depend on the subtype of diabetes mellitus being investigated. A previous study 
found that POAG was not associated with familial type-I or insulin-dependent diabetes 
mellii:us (Clark 1986). The significant associations found in the Blue Mountains Eye Study 
were attributed to most patients having type II or non-insulin-dependent diabetes mellitus 
(Mitchell 1997). To date, no definite evidence for stratified diabetes subtype has yet been 
found. 
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CHAPTER VIII 
RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
MIGRAINE HEADACHE 
114 
. 
RESULTS 
VIII.I Familial versus Sporadic Glaucoma Comparison 
Table VIII.1 - Unadjusted odds ratio of migraine in familial glaucoma compared to 
sporadic glaucoma group. 
Odds of Migraine p-value odds ratio 95% confidence interval 
Unadjusted Odds 0.5 0.88 0.60-1.29 
Other Risk Factors 0.6 0.90 0.60-1.33 
GIST scores 0.5 0.87 0.59-1.27 
Age and Gender 0.5 0.88 0.59-1.29 
There is no evidence of differences in odds of migraine between familial and sporadic 
glaucoma groups. 
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VIII.II Relationship of odds of having migraine versus GIST score 
The distribution of subjects across GIST scores is summarised in Table VIII.2. 
Table VIII.2 - Distribution of migraine versus no migraine and odds of migraine as a 
function of GIST scores in the familial glaucoma, sporadic glaucoma and unaffected 
groups. 
Number GIST Score 
MIGRAINE Group 0 0.5 0.7 0.8 0.9 1 Total 
FALSE Unaffected 26 566 592 
Familial 271 248 164 171 854 
Sporadic 265 190 91 66 612 
FALSE 26 566 536 438 255 237 2058 
Total 
TRUE Unaffected 2 148 150 
Familial 74 34 29 23 160 
Sporadic 31 31 5 9 76 
TRUE 2 148 105 65 34 32 386 
Total 
Grand Total 28 714 641 503 289 269 2444 
There were a greater number of people with no migraine compared to people with migraine 
across all GIST scores in all three groups. A total of 76 out of 688 (11.0%) in the sporadic 
glaucoma group had migraine, while a total of 166 9ut of 1014 (15.8%) in the familial 
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glaucoma group had migraine (Table VIII.2). Overall, a total of 236 glaucoma patients out 
of 1702 (13.9%) had migraine. 
Similar to diabetes mellitus, there were no significant differences among odds across GIST 
scores 0.7 to 1.0 (Figure VIII). 
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Figure VIII - Comparison of odds of migraine in familial glaucoma, sporadic 
glaucoma and unaffected groups. 
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VIII.III Relationship of Odds of Migraine versus Gender 
Table VIII.3 shows the number of males and females with and without migraine in all three 
groups. 
Table VIII.3 - Distribution of migraine versus no migraine in males and females in familial 
glaucoma, sporadic glaucoma and unaffected Groups. 
Count of Type Gender 
MIGRAINE Type F M Total 
TRUE Control 111 39 150 
Familial 116 44 160 
Sporadic 55 21 76 
TRUE Total 282 104 386 
FALSE Control 329 263 592 
Familial 465 389 854 
Sporadic 333 279 612 
FALSE Total 1127 931 2058 
1409 1035 2444 
Grand Total 
In the familial glaucoma group, migraine was found in 116 out of S81 females (20.0%) and in 
44 out of 433 males (10.2%). In the sporadic glaucoma group, migraine was found in SS out 
of 388 females (14.2%) and in 21 out of 300 males (7.0%). The differences were not 
statistically significant (OR 1.01; 9S%CI O.SS -1.90). 
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VIII.IV RELATIONSHIP TO DEGREE OF RELATIVES 
Table VIII.4 - Odds of migraine in subgroup of familial glaucoma versus sporadic glaucoma 
group as a function of degrees of relatives affected with POAG. 
Degree of Relative p-value odds ratio 95% confidence intervals 
lst 0.283 0.798 0.528 - 1.206 
2nd 0.664 1.204 0.520- 2.787 
3rd 0.302 1.660 0.635 - 4.342 
4th 0.468 0.787 0.413 -1.501 
As shown in Table VIII.4, subgroups of degrees of relatives in familial glaucoma 
demonstrated no significant difference in odds of migraine in comparison to the sporadic 
glaucoma group. 
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DISCUSSION 
There was a lack of significant association between familial glaucoma and migraine headache 
m this study (OR 0.88; 95%CI 0.60-1.29). Similarly, no significant association was found in 
the distribution of migraine between the familial and sporadic glaucoma groups as a function 
of degree of relatives affected with POAG, GIST scores (OR 0.87; 95%CI 0.59-1.27) or age 
and gender (OR 0.88; 95%CI 0.59-1.29). Indeed, the association between total POAG and 
migraine is still under considerable debate. 
A preponderance of studies has suggested ocular vasospasm as a risk factor for POAG, 
particularly low-tension glaucoma (Flammer 1992; Gaspar 1995; Winterkom 1995; Gasser 
1989; Drance 1988; Orgul 1994). Migraine, like Raynaud's phenomenon and Prinzmetal 
variant angina, may be part of a generalised vasospastic tendency (Flammer 1992; Gaspar 
1995; Orgul 1994; Gasser 1987; Gasser 1990; Miller 1981; Zahavi 1984). Vasospasm caused 
by lqcal ocular malformation and vascular dysregulation has also been associated with 
normal-tension glaucoma (Flammer 1998; Yamamoto 1998). 
Calcium channel blockers can potentially inhibit myogenic contraction and hence 
vasospasm; in selected cases of low-tension glaucoma, treatment with these agents reversed 
visual field defects (Gaspar 1995; Gasser 1989; Gasser 1987). 
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In a multivariate study, no difference between low-tension and high-tension glaucoma 
groups with respect to organic vascular pathologic findings was found (Carter 1990). Despite 
continumg controversy, it is reasonable to suggest that local perfusion pressure at the nerve 
head is an important variable in the development of POAG, regardless of IOP (Wilson 
1994). 
In the population-based Beaver Dam Eye Study, no association between POAG and 
migraine headache was found (Klein 993). In the more recent Blue Mountains Eye Study, for 
all age groups combined, there was no significant association between typical migraine 
headache (16.7% reported history of migraine) and POAG (16.6%) (OR 1.3; 95% Cl 0.8-
2.2), · after multivariate adjustment including glaucoma family history, diabetes, 
pseudoexfoliation, and hypertension (Wang 1997). 
Therefore, there is currently no evidence to suggest an association between familial POAG 
and migraine headache. 
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CHAPTER IX 
RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
CORTICOSTEROIDS 
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RESULTS 
IX.I Familial versus Sporadic Glaucoma Comparison 
Table IX.1 - Unadjusted odds ratio of corticosteroids use in familial glaucoma 
compared to sporadic glaucoma group. 
Odds of Corticosteroids p-value odds ratio 95% confidence interval 
Unadjusted Odds 0.75 1.05 0.80-1.37 
Other Risk Factors 0.68 1.06 0.80-1.40 
GIST Scores 0.80 1.04 0.80-1.37 
Age and Gender 0.74 1.05 0.80-1.37 
There is no evidence of differences in odds of corticosteroid use between familial and 
spor~dic glaucoma groups. 
123 
IX.IT Relationship of odds of Corticosteroids use versus GIST score 
The distribution of subjects across GIST scores is summarised in Table IX.2. 
Table IX.2-Distribution of corticosteroids use versus no corticosteroids use and odds 
of corticosteroids use as a function of GIST scores in the familial glaucoma, sporadic 
glaucoma and unaffected groups. 
Number GIST Score 
STEROIDS Group 0 0.5 0.7 0.8 0.9 1 Total 
FALSE Unaffected 25 554 579 
Familial 237 198 133 131 699 
, Sporadic 202 145 70 52 4~9 
FALSE 25 554 439 343 203 183 1747 
Total 
TRUE Unaffected 3 160 163 
Familial 108 84 60 63 315 
Sporadic 94 76 26 23 219 
TRUE 3 160 202 160 86 86 697 
Total 
Grand Total 28 714 641 503 289 269 2444 
There were a greater number of people who never used corticosteroids compared to people 
who had used corticosteroids at least once across all GIST scores in all three groups. A total 
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of 219 out of 688 (31.8%) in the sporadic glaucoma group had ever used corticosteroids at 
least once, while a total of 315 out of 1014 (31.1 %) in the familial glaucoma group had ever 
used corticosteroids (Table IX.2). Overall, a total of 534 glaucoma patients out of 1702 
(31.4%) had ever used corticosteroids. 
There are no significant differences among odds across GIST scores 0.7 to 1.0 (Figure IX). 
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Figure IX - Comparison of odds of corticosteroids in familial glaucoma, sporadic 
glaucoma and unaffected groups. 
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IX.III Relationship of Odds of Corticosteroids use versus Gender 
Table IX.3 shows the number of males and females with and without corticosteroid use in 
all three groups. 
Table IX.3 - Distribution of corticosteroids use versus no corticosteroids use in males 
and females in familial glaucoma, sporadic glaucoma and unaffected groups. 
Count of Type Gender 
STEROIDS Type F M Total 
TRUE Control 114 49 163 
Familial 183 132 315 
Sporadic 130 89 219 
TRUE Total 427 270 697 
FALSE Control 326 253 579 
Familial 398 301 699 
Sporadic 258 211 469 
FALSE Total 982 765 1747 
Grand Total 1409 1035 2444 
In the familial glaucoma group, steroid use was found in 183 out of 581 females (31.5%) and 
in 132 out of 433 males (30.5%). In the sporadic glaucoma group, steroid use was found in 
130 out of 388 females (33.5%) and in 89 out of 300 males (29.7%). The differences are not 
statistically significant (OR 0.95; 95%CI 0.67 - 1.40). 
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IX.IV Relationship to Degree of Relatives 
Table IX.4 - Odd_s of corticosteroid use in subgroups of familial glaucoma versus 
sporadic glaucoma group as a function of degrees of relative affected with POAG. 
Degree of Relative p-value odds ratio 95% confidence intervals 
1st 0.393 1.139 0.846 - 1.533 
2nd 0.992 0.997 0.582 - 1.710 
3rd 0.999 1.000 0.578 - 1.732 
4th 0.300 0.785 0496-1242 
As shown in Table IX.4, subgroups of degrees of relatives in familial glaucoma 
demonstrated no significant difference m odds of corticosteroid use compared to the 
sporadic glaucoma group. 
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DISCUSSION 
In this study, ever use of corticosteroids was not significantly different in terms of 
prevalence in the familial POAG group compared to the sporadic glaucoma group (OR 1.05; 
95%CI 0.80-1.37). Conversely, no significant association was found in the distnbution of 
corticosteroid use between the familial and sporadic glaucoma groups as a function of degree 
of relatives, GIST scores (OR 1.04; 95%CI 0.80-1.37) or age and gender (OR 1.05; 95%CI 
0.80-1.37). As this is a cross-section study, it lacks power to show temporal relationship 
between the two variables and provides no information on dose-effect response. Indeed, any 
true relationship between POAG and steroid responsiveness would be better explored in a 
smaller subgroup of patients whose steroid responsiveness is known, or can be tested by 
challenge with topical steroids. 
However, many studies have demonstrated that the use of oral or topical ophthalmic 
corticosteroids in a minority of people, called 'steroid responders', can lead to varying 
degrees of elevated IOP and predispose them to developing POAG (Becker 1963; 1965; 
Williamson 1969; Mitchell 1999). 
An earlier study reported that nearly all persons with a diagnosis of POAG were moderate-
to-high responders (Becker 1964). Ninety percent of patients with POAG were high 
responders to a six-week course of topical ocular betamethasone, during which their IOPs 
showed marked elevation (>30mmHg). The remaining 10% of patients with POAG showed 
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moderate response with a moderate elevation of IOP (22-30mm.Hg). Steroid responders in 
the normal population were also shown to have a higher risk of developing POAG over time 
(Lewis 1988; Kltazawa 1981). 
The Blue Mountains Eye Study reported a strong association between ever use of mhaled 
corticosteroids and findings of glaucoma or OH in persons with a family history of 
glaucoma (OR 2.6; Cl 1.2-5.8). Moreover, the risk increased with higher doses (OR 6.3; Cl 
1.0-38.6) for persons who used more than four puffs per day. However, no statistically 
significant association was found for persons with any family history of glaucoma, adding 
further support for a genetic mechanism in the association. 
A genetic basis for steroid-induced OH was postulated by some investigators in the 1960s 
(Becker 1964; Armaly 1967), but disputed by others (Francois 1966). Clinical studies have 
demonstrated that inheritance of steroid response may have an autosomal recessive pattern 
and may be associated with inheritance of glaucoma (Davies 1968; Bartlett 1993) in a rather 
complex manner (Clark 1995). It is interesting that both siblings and offspring of patients 
with POAG have increased responsiveness to steroids (30 and 25% respectively are high 
responders) (Richardson 1997). Recently, the discovery of the trabecular meshwork-induced 
glucocorticoid response (TIGR) gene or MYOC at the GLC1A locus and its multiple 
chsease-causing mutations in some 5% of hereditary glaucoma has added further support for 
the genetic basis (Fingert 1999). 
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One of its proteins, originally called TIGR, showed time-dependent induction with 
dexamethasone treatment over several weeks (Polansky 1997). Polansky and collaborators 
(1997) have also reported repression of steroid induction of l\1YOC mRNA in human 
trabecular meshwork in vitro by addition of the nonsteroidal anti-inflammatory drug 
diclofenac. Whether pharmacologic manipulation of the expression of this gene will benefit a 
subset of patients with POAG is yet to be determined. The promoter region of l\1YOC has 
been identified and contains regions (consensus motifs) that are responsive to 
glucocorticoids and a number of other hormones (Polansky 1998). This led to the hypothesis 
that sequence changes here or in other regulatory regions of l\1YOC or other glaucoma 
genes (Alward 1998; Kubota 1998) could be involved in development of steroid-induced 
glaucoma. Recently, however, a study using a cynomologus monkey model and DNA-
mutation screening of GLC1Amethods did not support the hypothesis and found no 
statistically significant evidence for a link between l\1YOC mutations and steroid-induced 
OH (Fingert 2001). Furthermore, in a Korean study, l\1YOC did not seem to be related to 
steroid-induced glaucoma (Kee 1997). 
At present, there is no significant difference in the odds of ever use of corticosteroids 
between familial and sporadic glaucoma groups. 
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CHAPTERX 
RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
SMOKING 
'When you know a thing, to hold that you know it, and when you do not know it, to admit 
that you do not know it - this is true knowledge" 
(Confucius) 
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RESULTS 
X.I Familial versus Sporadic Glaucoma Comparison 
Table X.1 - Unadjusted odds ratio smoking in familial glaucoma compared to 
sporadic glaucoma group. 
Odds of Smoking p-value odds ratio 95% confidence interval 
Unadjusted Odds 0.19 0.75 0.49 -1.15 
Other Risk factors 0.19 0.75 0.49 -1.15 
GIST scores 0.17 0.74 0.48-1.14 
Age and Gender 0.20 0.75 0.49-1.16 
Ther~ is no evidence of differences in odds of smoking between familial and sporadic 
glaucoma groups. 
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X.11 Relationship of odds of Smoking versus GIST score 
The distribution of subjects across GIST scores is summarized in table X.2 below. 
Table X.2 - Distribution of smoking versus no smoking and odds of smoking as a 
function of GIST scores in the familial glaucoma, sporadic glaucoma and unaffected 
groups. 
Number GIST 
Score ~ 
SMOKING Group 0 0.5 0.7 0.8 0.9 1 Total 
FALSE Unaffected 28 582 610 
Familial 295 250 170 174 889 
Sporadic 264 199 91 68 622 
FALSE 28 582 559 449 261 242 2121 
Total 
TRUE Unaffected 132 132 
Familial 50 32 23 20 125 
Sporadic 32 22 5 7 66 
TRUE 0 132 82 54 28 27 323 
Total 
Grand 28 714 641 503 289 269 2444 
Total 
There was a greater number of people who never smoked compared to people who ever 
smoked across all GIST scores in all three groups. A total of 66 out of 686 (9.6%) in the 
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sporadic glaucoma gtoup had smoked, while a total of 125 out of 1014 (12.3%) in the 
familial glaucoma group had smoked (Table X.2). Overall, a total of 191 glaucoma patients 
out of 1702 (11.2%) had smoked. 
There were no significant differences among odds of smoking across GIST scores 0.7 to 1.0 
(Figure X). 
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Figure X - Comparison of odds of smoking in familial glaucoma, sporadic glaucoma 
and unaffected groups. 
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X.111 Relationship of Odds of Smoking versus Gender 
Table X.3 shows the number of males and females with and without smoking in all three 
groups. 
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Table X.3 - Distribution of smoking versus no smoking in males and females in 
familial glaucoma, sporadic glaucoma and unaffected groups. 
Count of Gender 
Type 
SMOKING Type F M Total 
TRUE Control 66 66 132 
Familial 70 55 125 
Sporadic 24 42 66 
TRUE Total 16 163 323 
FALSE Control 374 236 610 
Familial 511 378 889 
Sporadic 364 258 622 
FALSE Total 1249 872 2121 
Grand Total 1409 1035 2444 
In ~e familial glaucoma group, 70 out of 581 females (12.0%) and 55 out of 433 males 
(12.7%) had smoked. In the sporadic glaucoma group, 24 out of 388 females (6.2%) and 42 
out of 300 males (14.0%) had ever smoked. The differences were not statistically significant 
(OR 2.23; 95%CI 1.0-4.1). 
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IX.IV RELATIONSHIP TO DEGREE OF RELATIVE 
Table X.4 - Odds of smoking in subgroups of familial glaucoma versus sporadic 
glaucoma group as a function of degrees of relatives affected with POAG. 
Degree of Relative p-value odds ratio 95% confidence intervals 
1st 0.379 0.810 0.508 - 1.294 
2nd 0.169 0.589 0.277 - 1.253 
3rd 0.692 0.841 0.357 - 1.982 
4th 0.181 0.628 0.318-1.242 
As shown in Table X.4, subgroups of degrees of relative in familial glaucoma demonstrated 
no significant difference in odds of having ever smoked in comparison to the sporadic 
glaucoma group. 
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DISCUSSION 
Glaucoma has been reported to be associated with increased alcohol consumption (Kahn 
1980) and cigarette smoking (Wilson 1987). However, in the Blue Mountains Eye study, 
smoking was demonstrated not to be statistically significantly associated with POAG, and 
adding smoking (current versus non-current or ever versus never) into the multivariate 
model comparing migraine and POAG did not alter results (Wang 1997). 
In this study, smoking was not significantly related to familial POAG (OR 0.75; 95%CI 0.49-
1.15). Similarly, no signific:;tnt association was found in the distribution of smoking between 
the familial and sporadic glaucoma groups as a function of degree of relatives, GIST scores 
(OR 0.74; Cl 0.48-1.14) or age and gender (OR 0.75; Cl 0.49-1.16). 
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CHAPTERXI 
RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
ATHEROSCLEROSIS 
139 
RESULTS 
XI.I Familial versus Sporadic Glaucoma Comparison 
Table XI.1 - Unadjusted and Adjusted Odds ratios and confidence intervals of 
atherosclerosis in familial glaucoma compared to sporadic glaucoma group. 
Adjustment p-value odds ratio 95% confidence interval 
None 0.03 0.70 0.50- 0 97 
Other Risk factors 0.04 0.71 0.51- 0.99 
GIST Scores 0.07 0.74 0.53-1.03 
Age and Gender 0.03 0.69 0.49- 0.95 
The unadjusted odds of athersclerosis was significantly different in the familial glaucoma 
group compared to the sporadic glaucoma group (OR 0.70; 95%CI 0.50-0.97). However, 
after adjusting for other clinical risk factors, the relationship is weakened (OR 0.71; 95%CI 
0.51-0.99). 
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XI.11 Relationship of odds of having Atherosclerosis versus GIST score 
The distribution of subjects across GIST scores is summarised in Table XI.2 below. 
Table XI.2 - Distribution of atherosclerosis versus no atherosclerosis and odds of 
atherosclerosis as a function of GIST scores in the familial glaucoma, sporadic 
glaucoma and unaffected groups. 
GIST 
Number Score 
ATHEROSCLE. Group 0 0.5 0.7 0.8 0.9 1 Total 
TRUE Unaffected 6 65 71 
Familial 72 47 45 54 218 
Sporadic 65 35 16 13 129 
TRUE Total 6 65 137 82 61 67 418 
FALSE Unaffected 22 649 671 
Familial 273 235 148 140 796 
Sporadic 231 186 80 62 559 
FALSE Total 22 649 504 421 228 202 2026 
Grand Total 28 714 641 503 289 269 2444 
There were a greater number of people who had no atherosclerosis compared to people who 
had atherosclerosis across all GIST scores in all 3 groups. A total of 129 out of 688 (18.8%) 
in the sporadic glaucoma group had atherosclerosis, while a total of 218 out of 1014 (21.5%) 
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in the familial glaucoma group had athersclerosis (Table XI.2). Overall, a total of 347 
glaucoma patients out of 1702 (20.4%) had atherosclerosis. 
There were no significant differences among odds of atherosclerosis across GIST scores 0. 7 
to 1.0 (Figure XI). 
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Figure XI - Comparison of odds of atherosclerosis in familial glaucoma, sporadic 
glaucoma and unaffected groups. 
It was interesting to note the difference between the familial glaucoma and sporadic group in 
respect to diminished likelihood of atherosclerosis. It became non-significant when the 
difference in GIST levels between the groups was removed (OR 0.74; 95%CI 0.53-1.03). 
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XI.111 Relationship of Odds of Atherosclerosis versus Gender 
Table XI.3 shows the number of males and females with and without atherosclerosis in all 
three groups. 
Table XI.3 - Distribution of atherosclerosis versus no atherosclerosis in males and 
females in familial glaucoma, sporadic glaucoma and unaffected Groups. 
Count of Type Gender 
ATHEROSC Type F M Total 
TRUE Control 42 29 71 
Familial 114 104 218 
Sporadic 70 59 129 
TRUE Total 226 192 418 
FALSE Control 398 273 671 
Familial 467 329 796 
Sporadic 318 241 559 
FALSE Total 1183 843 2026 
Grand Total 1409 1035 2444 
In the familial glaucoma group, atherosclerosis was found in 114 out of 581 females (19.6%) 
and in 104 out of 433 males (24.0%). In the sporadic glaucoma group, atherosclerosis was 
found in 70 out of 388 females (18.0%) and in 59 out of 300 males (19.7%). These 
differences were not statistically significant (OR 1.09; 95%CI 0.70 - 1.70). Indeed, the odds 
ratio of atherosclerosis in familial glaucoma compared to sporadic glaucoma is not affected 
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by adjustments for age and gender (OR 0.69; 95%CI 0.49-0.95), which is not surprising 
given that the two groups have a similar age and gender profile. 
XI.IV RELATIONSHIP TO DEGREE OF RELATIVE 
Table XI.4 - Odds of atherosclerosis in subgroups of familial glaucoma versus 
sporadic glaucoma group as a function of degrees of relatives affect,ed with POAG. 
Degree of Relative p-value odds ratio 95% confidence intervals 
1 SI 0.105 0.745 0.523 - 1.063 
znd 0.351 0.741 0.395 - 1.390 
3rd 0.053 0.553 0.303 -1.008 
4th 0.068 0.610 0.358 - 1.038 
Similar to GIST scores, no significant association was found in the distribution of 
atherosclerosis between the familial and sporadic glaucoma groups as a function of degree of 
relatives in the familial group. 
It seems that the analysis of the distribution of atherosclerosis across degree of relative in the 
familial glaucoma group does not support an atherosclerosis-familial POAG relationship. If 
a genetic effect exists, it is likely to be stronger in the first-degree relatives compared to the 
more distant blood relatives. Despite being limited by the relatively wide confidence intervals 
in this study, the odds of atherosclerosis compared to sporadic glaucoma in 1 •• degree 
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relatives of familial glaucoma is 0.745 (95%CI 0.523-1.063) versus 0.553 (95%CI 0.303-
1.00S) and 0.610 (0.358-1.038) in 3rd and 4'h degrees of relatives respectively. This suggests 
that a genetic association between atherosclerosis and familial POAG is unlikely. 
DISCUSSION 
The odds of atherosclerosis appear to be weakly significantly different between the familial 
glaucoma and sporadic glaucoma groups (OR 0.70; 95%CI 0.50-0.97) (p=0.03), and is 
unaffected by adjustments for other risk factors (OR 0.71; 95%CI 0.51-0.99) or age and 
gender (OR 0.69; 95%CI 0.49-0.95). However, standardising GIST scores rendered the 
association non-significant (OR 0.74; 95%CI 0.53-1.03). Furthermore, there is no significant 
_ association between degrees of relatives in the familial glaucoma group and sporadic 
glaucoma. With relatively large confidence intervals, these findings are likely to reflect a 
chance finding, but an independent study can provide more definite answers. 
Indeed, the degree of atherosclerosis may not correlate closely with self-reported end-organ 
symptoms, and any true relationship between POAG and atherosclerosis might be better 
explored by correlating with the actual extent of disease measured with carotid 
ultrasonography. 
At present, therefore, there is insufficient evidence to show a significant association between 
atherosclerosis and familial POAG. 
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CHAPTER XII 
RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
COLD EXTREMITIES 
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RESULTS 
XII.I Familial versus Sporadic Glaucoma Comparison 
Table XII.1 - Unadjusted odds ratio of cold extremities in familial glaucoma 
compared to sporadic glaucoma group. 
Odds of Cold Extremities p-value odds ratio 95% confidence interval 
Unadjusted Odds 0.5 0.92 0.71-1.20 
Other Risk factors 0.8 0.97 0.73-1.27 
GIST scores 0.6 0.93 0.71--1.21 
Age and Gender 0.5 0.92 0.70-1.19 
There is no evidence of differences in odds of cold extremities between familial and sporadic 
glaucoma groups. 
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XII.II Relationship of odds of having Cold Extremities versus GIST 
score 
The distribution of subjects across GIST scores is summarised in Table XII.2 below. 
Table XII.2 - Distribution of cold extremities versus no cold extremities and odds of 
cold extremities as a function of GIST scores in the familial glaucoma, sporadic 
glaucoma and unaffected groups. 
Number GIST 
Score 
COLi) Group 0 0.5 0.7 0.8 0.9 1 Total 
EXTREM. 
FALSE Unaffected 25 552 577 
Familial 224 192 117 126 659 
Sporadic 205 145 66 51 467 
FALSE Total 25 552 429 337 183 177 1703 
TRUE Unaffected 3 162 165 
Familial 121 90 76 68 355 
Sporadic 91 76 30 24 221 
TRUE Total 3 162 212 166 106 92 741 
Grand Total 28 714 641 503 289 269 2444 
There were a greater number of people who had no cold extremities compared to people 
who had cold extremities across all GIST scores in all three groups. A total of 221 out of 688 
(32.1 %) in the sporadic glaucoma group had cold extremities, while a total of 355 out of 
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1014 (35.1 %) in the familial glaucoma group had cold extremities (fable XIl.2). Overall, a 
total of 576 glaucoma patients out of 1702 (33.8%) had cold extremities. 
There were no significant differences among odds of cold extremities across GIST, scores 
0.7 to 1.0 (Figure XII). 
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Figure XII - Comparison of odds of cold extremities in familial glaucoma, sporadic 
glaucoma and unaffected groups. 
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XII.III Relationship of Odds of Cold Extremities versus Gender 
Table XII.3 shows the number of males and females with and without cold extremities in 
all three groups 
Table XII.3 - Distribution of cold extremities versus no cold extremities in males 
and females in familial glaucoma, sporadic glaucoma and unaffected groups. 
Count of Type Gender 
COLD Type F M Total 
EXTREM 
TRUE Control 124 41 165 
Familial 227 128 355 
, 
Sporadic 125 96 221 
TRUE Total 476 265 741 
FALSE Control 316 261 577 
Familial 354 305 659 
Sporadic 263 204 467 
FALSE Total 933 770 1703 
Grand Total 1409 1035 2444 
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In the familial glaucoma group, cold extremities were found in 227 out of 581 females 
(39.1%) and in 128 out of 433 males (29.6%). In the sporadic glaucoma group, cold 
extremities were found in 125 out of 388 females (32.2%) and in 96 out of 300 males 
(32.0%). The differences were not statistically significant (OR 0.73; 95%CI 0.52 -1.04). 
XII.IV Relationship to Degree of Relative 
Table XII.4 - Odds of cold extremities in subgroups of familial glaucoma versus 
sporadic glaucoma group as a function of degrees of relative affected with POAG. 
Degree of Relative p-value odds ratio 95% confidence intervals 
1st 0.451 0.895 0.671 -1.194 
2nd 0.506 1.205 0.695 - 2.089 
3rd 0.835 1.060 0.613 - 1.834 
4th 0.329 0.797 0.505 -1.257 
As shown in Table XII.4, subgroups of degrees of relative in familial glaucoma 
demonstrated no significant difference in odds of cold extremities compared to the sporadic 
glaucoma group. 
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DISCUSSION 
There was no significant association between cold extremities, which reflect vasospasm of 
peripheral arteries, and familial POAG (OR 0.92; 95%CI 0.71-1.20). Conversely, no 
significant association was found in the distribution of cold extremities between the familial 
and sporadic glaucoma groups as a function of degree of relatives, GIST scores (OR 0.93; 
95%CI 0.71-1.21) or age and gender (OR 0.92; 95%CI 0.7-1.19). 
The lack of a significant association between cold extremities and familial POAG supports 
the absence of a significant association between migraine and familial POAG, which 
presumably occurs via a similar vasospastic mechanism. 
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CHAPTER XIII 
.RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
BLOOD TRANSFUSION 
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RESULTS 
XIII.I Familial versus Sporadic Glaucoma Comparison 
Table XIII.1 - Unadjusted odds ratio of blood transfusion in familial glaucoma 
compared to sporadic glaucoma group. 
Odds of Transfusion p-value odds ratio 95% confidence interval 
Unadjusted Odds 0.96 0.99 0.73-1.36 
Other Risk factors 0.77 1.05 0.76 -1.45 
GIST scores 0.99 0.99 0.73-1.37 
Age and Gender 0.91 0.98 0.72-1.70 
There is no evidence of differences in odds of blood transfusion between familial and sporadic 
glaucoma groups. 
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XIILIIRelationship of odds of having Transfusion versus GIST score 
The distribution of subjects across GIST scores is summarised in Table XIII.2 below. 
Table XIII.2 - Distribution of transfusion versus no transfusion and odds of 
transfusion as a function of GIST scores in the familial glaucoma, sporadic glaucoma 
and unaffected groups. 
GIST 
Number Score 
TRANSFUSION Group 0 0.5 0.7 0.8 0.9 1 Total 
FALSE Unaffected 25 617 642 
Familial 269 230 142 131 804 
Sporadic 223 173 7.8 63 537 
FALSE Total 25 617 492 403 233 213 1983 
TRUE Unaffected 3- 97. 100 
Familial 76 52 38 44 210 , 
Sporadic 73 48 18 12 151 
TRUE Total 3 97 149 100 56 56 461 
Grand Total 28 714 641 503 289 269 2444 
There were a greater number of people who had had no blood transfusion compared to 
people who had had transfusion across all GIST scores in all three groups. A total of 151 out 
of 688 (21.9%) in the sporadic glaucoma group had had a transfusion, while a total of 210 
' 
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out of 1014 (20.7%) in the familial glaucoma group had a had transfusion (Table XIIl.2). 
Overall, a total of 361 glaucoma patients out of 1702 (21.2%) had had a transfusion. 
There was no significant differences among odds of blood transfusion across GIST scores 
0.7 to 1.0 (Figure XIII). 
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Figure XIII - Comparison of odds of transfusion in familial glaucoma, sporadic 
glaucoma and unaffected groups. 
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XIII.III Relationship of Odds of Transfusion versus Gender 
Table XIII.3 shows the number of males and females with and without transfusion in all 
three groups. 
Table XIII.3-Distribution of transfusion versus no transfusion in males and females 
in familial glaucoma, sporadic glaucoma and unaffected Groups. 
Count of Type Gender 
TRANSFUSION Type F M Total 
TRUE Control 71 29 100 
Familial 131 79 210 
Sporadic 103 48 151 
TRUE Total 305 156 461 
FALSE Control 369 273 642 
Familial 450 354 804 
Sporadic 285 252 537 
FALSE Total 1104 879 1983 
Grand Total 1409 1035 2444 
In the familial glaucoma group, 131 out of 581 females (22.5%) and 79 out of 433 males 
(18.2%) had had a blood transfusion. In the sporadic glaucoma group, 103 out of 388 
females (26.5%) and 48 out of 300 males (16.0%) had had a blood transfusion. The 
differences were not statistically significant (OR 0.77; 95%CI 0.50 -1.21). 
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XIII.IV Relationship to Degree of Relative 
Table XIII.4 - Odds of blood transfusion in subgroups of familial glaucoma versus sporadic 
glaucoma group as a function of degree of relative affected with POAG. 
Degree of Relative p-value odds ratio 95% confidence intervals 
1st 0.909 1.020 0.723 -1.439 
2nd 0.045 0.565 0.323 - 0.988 
3rd 0.839 1.070 0.557-2055 
4th 0.283 1.391 0.761 - 2.541 
As shown in Table XIII.4, subgroups of degrees of relative in the familial glaucoma group 
demonstrated no significant difference in odds of blood transfusion compared tothe 
sporadic glaucoma group, except for the 2"d degree relatives (p=0.045). However, it would 
appear to be reasonable to attribute this difference to chance variation since in the absence 
of any difference, 1 in 20 will on average have a p-value less than 0.5 
DISCUSSION 
There was no significant association between blood transfusion, which presumably put 
haemodynamic stress on blood vessels, and familial POAG (OR 0.99; 95%CI 0.73-1.36). 
Conversely, no significant association was found in the distribution of blood transfusion 
between the familial and sporadic glaucoma groups as a function of degree of relatives, GIST 
scores (OR 0.99; 95%CI 0.73-1.37) or age and gender (OR 0.98; 95%CI 0.72-1.70). 
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CHAPTER XIV 
RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
THYROID DISORDERS 
159 
RESULTS 
XIV.I Familial versus Sporadic Glaucoma Comparison 
Table XIV.1 - Unadjusted odds ratio of thyroid disorder in familial glaucoma 
compared to sporadic glaucoma group. 
Odds of Thyroid Disorder p-value odds ratio 95% confidence interval 
Unadjusted Odds 0.7 0.92 0.61-1.38 
Other Risk factors 0.8 0.94 0.62-1.44 
GIST scores 0.6 0.88 0.58-1.34 
Age and Gender 0.6 0.90 0.59-1.36 
There is no evidence of differences in odds of thyroid disorder between familial and 
sporadic glaucoma groups. 
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XIV.II Relationship of odds of Thyroid disorders versus GIST score 
The distribution of subjects across GIST scores is summarised in Table XIV.2 below. 
Table XIV.2-Distribution of thyroid disorders versus no thyroid disorders and odds of 
thyroid disorders as a function of GIST scores in the familial glaucoma, sporadic 
glaucoma and unaffected groups. , 
Number GIST 
Score 
THYRIOD Group 0 0.5 0.7 0.8 0.9 1 Total 
FALSE Unaffected 23 657 680 
Familial 295 248 171 178 892 
Sporadic 262 196 91 66 615 
FALSE 23 657 557 444 262 244 2187 
Total 
TRUE Unaffected 5 57 62 
Familial 50 34 22 16 122 
Sporadic 34 25 5 9 73 
TRUE 5 57 84 59 27 25 257 
Total 
Grand 28 714 641 503 289 269 2444 
Total 
There were a greater number of people who had no thyroid disorders (n=2187) compared to 
people who had thyroid disorders (n=257) across all GIST scores in all three groups. A total 
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of 73 out of 688 (10.6%) in the sporadic glaucoma group had thyroid disorders, while a total 
of 122 out of 1014 (12.0%) in the familial glaucoma group had thyroid disorders (Table 
XIV.2). Overall, a total of 195 glaucoma patients out of 1702 (11.5%) had thyroid disorders. 
Ther~ were no significant differences among odds of thyroid disorder across GIST scores 
0.7 to 1.0 (Figure XIV). 
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Figure XIV - Comparison of odds of thyroid disorders in familial glaucoma, sporadic 
glaucoma and unaffected groups. 
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XIV.III Relationship of Odds of Thyroid Disorders versus Gender 
Table XIV.3 shows the number of males and females with and without thyroid disorders in 
all 3 groups. 
Table XIV.3 - Distribution of thyroid disorders versus no thyroid disorders in males 
and females in familial glaucoma, sporadic glaucoma and unaffected Groups. 
Count of Type Gender 
THYROID Type F M Total 
TRUE Control 54 8 62 
Familial 102 20 122 
Sporadic 57 16 73 
TRUE Total 213 44 257 
-
FALSE Control 386 294 680 
Fanulial 479 413 892 
Sporadic 331 284 615 
FALSE Total 1196 991 2187 
Grand Total 1409 1035 2444 
In the familial glaucoma group, thyroid disorders were found in 102 out of 581 females 
(17.6%) and in 20 out of 433 males (4.6%). In the sporadic glaucoma group, thyroid 
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disorders were found in 57 out of 388 females (14.7%) and in 16 out of 300 males (5.3%). 
The differences were not statistically significant (OR 0.70; 95% Cl 0.34-1.50). 
XIV.IV Relationship to Degree of Relative 
Table XIV.4 - Odds of thyroid disorders in subgroups of familial glaucoma versus 
sporadic glaucoma group as a function of degrees of relative affected with POAG. 
Degree of Relative p-value odds ratio 95% confidence intervals 
lst 0.762 1.074 0 676-1.709 
2nd 0.953 1.026 0.440-2 393 
3rd 0.015 0.434 0.221 - 0.851 
4th 0.733 0.884 0.435 -1.795 
As shown in Table XIV.4, there was a significant difference in odds of thyroid disorder 
between familial glaucoma subjects with an affected third- or fourth-degree relative 
compared to sporadic glaucoma subjects. However the association became non-significant 
when familial glaucoma subjects with an affected 1st, 2nd or 4th degree relative was 
considered. This is likely to be a chance variation given 1 in 60 will produce a similar 
difference and a dilutional effect of a genetic association is not demonstrated. 
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DISCUSSION 
At present, there is insufficient evidence to support a significant association between thyroid 
disorders and familial POAG (OR 0.92; 95%CI 0.61-1.38). Similarly, no significant 
association was found in the distribution of thyroid disorders between the familial and 
sporadic glaucoma groups as a function of degree of relatives, GIST scores (OR 0.88; 
95%CI 0.58-1.34) or age and gender (OR 0.90; 95%CI 0.59-1.36). 
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CHAPTER XV 
RESULTS, STATISTICAL ANALYSIS & DISCUSSION -
RELATIONSHIP OF RISK FACTORS TO 'CONTROLS' 
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XV.I Comparing 'Controls' versus Familial and Sporadic Glaucoma 
groups 
Table XV.1 summarises the odds of various clinical risk factors in the total (familial and 
sporadic) glaucoma group compared to the 'control' unaffected group. 
Risk Factor p-value Odds Ratio 95% Confidence Intervals 
Hypertension 0.20 1.162 0.92-1.50 
Smoking 0.99 1.00 0.75-1.30 
Diabetes <0.01 2.67 1.70-430 
' 
Transfusion 0.79 1.04 0.79-1.40 
Atherosclerosis 0.89 0.98 0.72-1.30 
Cold extremities 0.05 1.27 1.01 -1.60 
Thyroid dtsorder 0.67 0.93 0.66-1.30 
M1gra111e 022 0.85 0.65-1.10 
Ster1ods <001 142 1.10-1.80 
XV.1 - Age-Gender adjusted Odds Ratios and Confidence Intervals for various 
clinical risk factors comparing total glaucoma and 'control' unaffected group. 
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As shown in table XV.1, the prevalence of diabetes mellitus is significantly higher in the total 
glaucoma group compared to the 'control' unaffected group (age-gender adjusted OR 2.67; 
95%CI 1.7-4.3). Similarly, ever use of corticosteroids is significantly more prevalent in the 
total glaucoma group in comparison to the 'control' group (age-gender adjusted OR 1.42; 
95%CI 1.1-1.8). No significant difference is found for the other seven clinical risk factors 
(hypertension, smoking, transfusion, atherosclerosis, cold extremities, thyroid disorders and 
migraine). 
DISCUSSION 
In this study, diabetes mellitus is significantly more prevalent in the total glaucoma group 
compared to the 'control' group (age-gender adjusted OR 2.67; 95%CI 1.7-4.3) in a 
magnitude similar to that found by the Blue Mountains Eye Mountain (age-gender adjusted 
OR 2.82; 95%CI 1.35-5.87). 
Ever use of corticosteroids is also significantly associated with the total glaucoma group 
compared to the 'control' group (age-gender adjusted OR 1.42; 95%CI 1.1-1.8). 
For the other seven risk factors there is no evidence to reject the hypothesis that odds of 
true;false is the same for the total glaucoma and 'control' groups. However, as discussed in 
chapter V, the unaffected 'control' group has a substantially younger age profile (median age52 
years) than the total glaucoma group (median age 74 years) and this may account for the 
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differences. It must be noted that age-adjusted comparisons are sensible given that the 
difference in the age patterns is a characteristic of the groups rather than an artefact of the 
sampling process. Since the risk of glaucoma is age-dependent, to make an age adjustment may 
create an artificial population unlike that in the natural world. That is, the assumption that 
prevalence with age increases in the same manner for the total glaucoma and 'control' groups 
may not be valid. 
For gender, however, there is no significant c.hfference in the male/female distribution in the 
total glaucoma group compared to the 'control' group (OR 1.102; 95% Cl 0.925-1.313) 
Comparisons between the glaucoma groups and the unaffected 'control' group must be 
considered carefully. As the 'control' group consists of individuals who have a GIST score of 
0.5 or less, and may be related to a glaucoma sufferer, they may not truly represent the 
normal population with no definite glaucoma. Indeed, some of these individuals may be too 
young to develop glaucomatous signs at the time of examination, but have potential for 
developing POAG later on in life. 
Because this is a cross-sectional study, it has important limitations. Exposure and disease are 
assessed at the same point in time, making it impossible to determine whether exposure 
preceded or followed the occurrence of disease. Further studies are required to assess 
possible associations suggested by data. Cohort or longitudinal studies are ideal as subjects 
are followed for a specific period of time for the occurrence of disease in each exposure 
group, allowing assessment of the temporal relationship between exposure and the disease 
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and the development of multiple outcomes from a single exposure. However, this would 
pose the problems of the expense of following a large group of people for a long period of 
time and the difficulty of retaining people in the study to minimise losses to follow-up. This 
would ensure the validity of study. 
The strengths of the present study are the objective examination and grading of POAG, 
relative large sample size and random distribution of glaucoma patients throughout 
Tasmania. Selection biases were minimised by identifying patients from the same general 
ophthalmology practices-based cohort rather than referral centres or specialty clinics. 
Thorough data collection was possible with a relatively high participation rate (77.1 % after 
appli~ation of exclusion criteria), wluch did not differ markedly between the familial and 
sporadic glaucoma groups. Ascertainment of probands and relatives was high. Interview bias 
was reduced because the study personnel were unaware of the study hypotheses and 
interviewers followed standard forms and procedures. Each feature of glaucoma was 
assessed separately in a blinded fashion to avoid biased diagnosis. Differences in technicians 
administering visual fields were inevitable. However, misclassification was unlikely using the 
standardised GIST scoring system. Ascertainment and self-selection biases may be present as 
' the study was patient-based. Reporting of family history may be subject to recall bias, 
severity of glaucoma and the under-diagnosis of glaucoma in the community. However, this 
was minimised by comparing the genealogic information with the objective examination 
findings of extended pedigrees rather than relying on history data. Investigation using 
laboratory identification of mutations in the GLC1A gene eliminated the problems 
associated with family history recall in an extension study of a chosen pedigree in chapter VI. 
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CHAPTER XVI 
CONCLUSIONS, IMPLICATIONS & 
RECOMMENDATIONS FOR FUTURE RESEARCH AND 
PRACTICES 
'This is not the end It is not even the beginning of the end. But it is, 
perhaps the end of the beginning" 
(Winston Churchil~ 
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XVI.I CONCLUSIONS 
Glaucoma Characteristics - Family History. Age and Gender 
In this study, 59.6% of all glaucoma subjects had a positive family history of POAG based 
on objective examinations and the GIST score system together with genealogic data. 
There was no significant difference in the distribution of gender between the familial and 
sporadic glaucoma groups (OR 1.053; 95% Cl 0.819 - 1.353), presumably explained by the 
autosomal inheritance of familial POAG. 
There were more females (43.1%) in the total glaucoma group compared to the 'control' 
unaffected group (40.7%), but the difference was insufficient to reach statistical significance 
(OR 1.102; 95% Cl 0.925 - 1.313). The implications of this are limited by the definition of 
the unaffected 'control' group, whereby some individuals classified as normal at time of 
examination may still potentially develop glaucoma at a later date. In addition, there are 
proportionately more females with increasing age and the average age of the females in the 
glaucoma group was 18 years older than the average age of the females in the unaffected 
group. 
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In both the familial (p<0.001) and sporadic (p<0.001) glaucoma groups, there is a non-linear 
decline in the proportion of subjects and increasing GIST scores, suggesting the possibility 
of a higher mortality rate associated with higher severity of POAG, but further investigation 
is required for clarification. 
The "distribution of GIST scores in familial glaucoma was skewed towards the higher 
spectrum and was significantly different from that of sporadic glaucoma (p<0.001 ), 
suggesting the possibility of an earlier onset and/ or greater severity of glaucomatous changes 
in the familial glaucoma group. However, this interpretation may be limited because 
although the GIST score correlates with severity, it is actually a score of certainty of 
diagnosis of glaucoma. On the other hand, there is some evidence that certain mutations of 
the myocilin gene, such as Thr377met and Tyr377His, are associated with an earlier age of 
onset of POAG, higher peak IOPs and greater likelihood of undergoing glaucoma drainage 
surgery (Mackey in press, Alward 1998). 
Age and gender were significant confounders in comparing familial and sporadic glaucoma 
groups, and should be considered in all future glaucoma studies. 
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Clinical Risk Factors - Familial versus Sporadic Glaucoma/ GIST 
Scores/ Degree of Relative Distributions 
Keeping in mind the drawbacks of a study limited to a specific geographical area that 
depends on voluntary responses from its subjects and on sampling techniques, this thesis 
purports that there are no significant differences between familial POAG and sporadic 
PO.AG in the nine risk factors tested (hypertension, diabetes mellitus, migraine, 
corticosteroid use, smoking, atherosclerosis, cold extremities, blood transfusion, thyroid 
disorders). 
In this investigation, there was initially a weak significant difference in odds of 
atherosclerosis between the familial and sporadic glaucoma groups (OR 0.70; 95%CI 0.50-
0.97), which is unaffected by age and gender (95%CI 0.69; 95%CI 0.49-0.95) or by other 
potential risk factors (OR 0.71; 95%CI 0.51-0.99). However,- the significance is lost after 
adjus.ting for GIST scores differences between the two groups (OR 0.74; 95%CI 0.53-1.03). 
In addition, the genetic association between degrees of relative subgroups of familial 
glaucoma and sporadic glaucoma is not substantiated in the current study. 
The distributions of the remaining eight risk factors (hypertension, diabetes mellitus, 
smoking, migraine, transfusion, cold extremities, thyroid disorders and ever use of 
corticosteroids) were not significantly different between the two glauwma subgroups after 
adjusting for other risk factors, GIST scores and age and gender. 
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The difference for blood transfusion was not significant in the 1 •t, 3rd or 4th -degree relatives 
subgroups, but was weakly significant in the 2°d degree relative subgroup (OR 0.565; 95% Cl 
0.323-0.988)(p=0.045). Similarly, the difference for thyroid disorder was not significant in 
the 1 ", 2nd or 4th degrees relative subgroups, but was significant in the 3rd degree relative 
subgroup (OR 0.434; 95% Cl 0.221-0.851). This anomaly may be attributed to spurious 
aberrations yet to be identified, or may be a consequence of chance in sampling in the study. 
An extension of the study highlighted that there were no significant differences (p=0.4) in 
the prevalence of hypertension between subjects with and without laboratory-tested 
mutations in the GLC1A gene in the gTas02 pedigree of the familial glaucoma group. This 
implies that there is insufficient evidence from the current findings to establish a significant 
association between hypertension and familial POAG. 
Clinical Risk Factors - Familial versus Sporadic Glaucoma/ Pedigree 
Distributions 
To the knowledge of the author, no previous study to date has examined entire glaucoma 
families in such detail, including both affected and unaffected family members. The sizes of 
individual pedigrees, however, were still too small for valid statistical comparison of the odds 
of risk factors in each pedigree of the familial glaucoma group versus the sporadic glaucoma 
group. 
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Clinical Risk Factors -Total Glaucoma versus 'Controls" Group 
The distributions of diabetes mellitus (age~gender adjusted OR 2.67; 95%CI 1.7-4.3) and 
corticosteriods (OR 2.82; 95%CI 1.35-5.87) are significantly different in the total (familial 
and sporadic) glaucoma group compared to the unaffected 'Controls' group. In contrast, the 
other seven clinical risk factors (hypertension, atherosclerosis, smoking, migraine, 
transfusion, cold extremities and thyroid disorders) are not significantly different between 
the two groups. However, this must be interpreted with reservation given the younger age 
profile of the 'controls' group because some individuals in this group may potentially 
develop POAG later on in life. 
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XVI.II IMPLICATIONS AND FUTURE RECOMMENDATIONS 
The suggestion of earlier onset or greater severity of disease in the familial POAG group 
should be further investigated or should at least be complemented with data on age at first 
diagnosis of glaucoma because the age of onset of glaucoma is rather insidious. 
In POAG, peripheral vision loss precludes many individuals from holding a driver's licence 
and decreases quality of life. Blindness in advanced stages of the disease is associated with 
significant mortality and morbidity (Weih 2000; McCarty 2001). 
Although a high proportion (97%) of people have heard of glaucoma (Attebo 1997), only 
half are diagnosed in the community (Mitchell 1996; Wensor, 1998). Treatment slows 
progression of the disease in many cases (Mao 1991; Smith 1986) and those patients who 
have well-controlled IOP with surgery do not seem to progress as rapidly in terms of visual 
field defects or optic disc pathology (McNaught et al 2000). 
At present, it is recommended that patients with a positive family history of glaucoma in 
first-degree relatives should be screened from the age of 40 years. If the initial assessment is 
normal, this is followed by 2-yearly checks until the age of 50 years and then annually 
thereafter (Kanski, 1999). The advantage of finding a genetic association is twofold: to be 
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able to identify individuals at risk of POAG that is readily treated if diagnosed early and to 
better understand the underlying defect that causes POAG and possibly improve rationale 
for treatment. 
If a real relation exists between atherosclerosis and familial POAG, it is likely to be modest 
and can be better explored by correlating with the extent of disease measured with carotid 
ultrasonography. However, the association is more likely to be spurious given current 
understanding that atherosclerosis is closely linked to cardiovascular risk factors such as 
hypertension, diabetes and smoking, and adjusting for these risk factors nearly eliminated the 
statistical significance in the relationship (OR 0.71; 95%CI 0.51-0.99). Nevertheless, there 
remains a need to develop strategies in glaucoma education for the community that help to 
target individuals with POAG risk factors who may be less likely to visit a general 
practitioner or ophthalmologist. 
Indeed, the discovery of GLC1A allows the possibility for predictive DNA testing in family 
members in appropriate circumstances under strict guidelines (Mackey 1998), and this study 
has been an extremely worthwhile investigation even though it did not discover any 
significant clinical risk markers for familial POAG with current data. 
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Appendix A 
GIST Gfa11~0111a lnbcritancc Stndy in Ta~mani.i 
a collabor:itivc project of the 
Informed Consent 
University ofTi1~mania, 
Eyr, Dqlartment; Royal Hobart Hospital 
Lh i:rpoul St. 
Unh·crsity of Melbourne, 
HOBAR'fTas 7000 
Ph & Fax 03) 6222 8553 
CONSENT FOR DNA TESTING 
l)cpartmcnt ofOJ>hthalmology 
Royal Victorian Eye & Ear Hospital, 
32 Gishorne St, 
EAST MELBOURNE Vi~ 3002 
Pll & Fax 03) 9929 8713 
Information for putients in the Glaucoma Inheritance Study (GIST). 
The glaucoma inheritance study is looking for families \Vith ~Jaucoma to find the 
genes that callsc glaucoma. We are inviting individuals and families who arc affocted 
with glaucoma to be involved in the study. This is at no cost to you. We wish to take 
a blood sample, or a mouth swab to test your D~A to sec ifwc can find the mutations 
in the first gene that we have discovered lhat causes glaucoma. If this first gene is not 
affected we mav llSC the DNA to help discover the other genes that lead to glaucoma. 
You are under no obligation to provide this and it may not Cali'\' anv direct benefit to 
your gl~uco~a management, but it may assist us in undersl:mdlng \vho else in your 
family is at nsk of glaucoma. 
The D?\A wil! be tested and we mav find: A change in the DNA, no change in the 
D>l'A, or be unable to find anything'. You will be infonncd <>fthe result of your test 
and be able to discuss this with us at any time. 
The DNA will be stored at the Universities of Tasmania and Melbourne. The results 
of anv scientific development will be owned by the Universities of Tasmania and 
Mclboome and their collaborators. You may ask to withdraw from the study at any 
time, without prejudice, and have vour sample destroyed. We may do further studies 
on glaucoma at a later date and will of course inform you of your results. In our work 
we may find other abnonnalitics of the DNA and will discuss the results with you. 
We may also firid that you are distantly related to other families that we have studied. 
based on the DNA findings. These results may all be published but will never identify 
you specifically. 
We will give you a copy of this form to keep for future reference. For more details or 
any questions please contact Dr David Mackey on the above numbers or leave a 
message. If you have any questions about the ethical nature of this study you may 
contact Dr Rosalie Parton of the RHH ethics committee on 03)6222 8226. 
Please sign this form to certLf)" that you read and understood the Informatio11 sheet, 
and had explained the nature and possible outcomes from the DNA testing and your 
questions have been answered lo your satisfaction. 
I am happy to participate i11 the (;faucoma Inllerilattce Study GIST. 
Name 
This is a copy tor your records 
Continued on next puge 
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NAME 
Please tick one of the following if these apply to you: 
I do not wish to participate in this study ............... .. 
Or 
I am interested but unable to participate today .......... . 
Or 
I am interested but do not want a blood test ............... . 
Or 
If you are interested please complete the forms over the page. 
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AppendixB Patient Family History Survey 
~· 
<D> 
GIST Glaucoma lnheritan<-e Study. 
Your Name .................................................... . 
Spo1L'e' name ............ . 
Plaw of Birth ... .. .. . . ............ . 
Please an>wer the tollowing to rho be.>1 of your abihty Lc.1ve bi.ink rl'unknown 
Your father's name ........ . dute of birth . . J. J • •• Place ..•. 
Your fmltcr's father's name.. . . . . . ... .. . . .. •. .. .. . .. .... . .. dare ofbrnlt . J.. . ./ ...... Place. 
Your father's mother's full name. .. .. .. .......... • ............. date of birth ... I .. .I ..... Pl<1cc 
(and maiden name) 
Your mother's name .... 
(and maiden name) 
date ofbJrth ... .I . . J .. .... Place . 
Your mother's father's name ............. , . . ............... date of birth • '· .J ..... Place 
Your mother's mother's full name ........ . 
(and maiden name) 
Name$ ot your brothers and s1srers 
(First and &urnames 
with married names of >isters, 
please note if dcteased 
If insufficient space please 
use tl1e reverse of this 
'heet or altach l"t) 
Names of your eh ildren . .. . 
.. .. • • ... date ofl>utll • . J .f. ... Place ......... . 
• . . .. • ......... date of birth 
Other llelative• affocted with glaucoma (pleMe llQtc if decea.;cd) 
Name 
. . . RelotioMhrp. . . . .. .. . .... Addrcs. . 
N"me. .............. RelJlionslup . .. . ....... Addre.~s .. 
Name ........... . 
.. .. ... Relnt1onsh1p . • • ......... Addres>. . 
Name ...................... . .. Rel:111onslnp • . • ...... Addre5s ........ . 
Name ..................................................... Relaliun•lup ....... .... •• . • . Addres• ........ . 
Name.. . .... • .. ...... ... .. .. .. . .. ................ Relnt;onslup.. .. . .. . .. • . Address ...... . 
L' anyone trJcing the fom1ly tree? Name aod Address ......... . 
Could you please attach or forward a copy ofyonr family uee? 
Thank you for your help with the Glauconrn lnherilllnoo Study 
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Appendix C 
Predilation Exam: Right 
Acuity: 
Refraction: Distance 
and/or Readers 
IOP: 
Gonioscopy: 
Anterior Segment 
Dilated Kxam: .'lo 1 Right 
Cup/Disc ratio 
Disc Size (S,M,L) 0 Other.Diseas~ 
Stercophoto-or Dilated Exam: No 2 R~ght 
Cup/Disc ratic} 
Disc Size (';,M,L) 0 Other Disease 
Stercophoto or Dilated Exam: ~o 3 Rigl1t 
Cup/Disc ratio 
Disc Size (S.M,L) 
Other Disease 
Field Score 
Reliability 
Score:A,B,C,D: 
GIST Field Score 
0 
Right Len 
Concordance between field and discs? 
Examination Protocol 
ScorcR L 
Score R 
Score R 
Yes/No 
Left Tick when do c 
Left 
Q. 
siimature 
Left 
0 
L si<matute 
Left 
0 
L signature 
~n~ 
Field 
Prc1s 
Dilat 
Blot 
Pho 
d 
0 
r Lette 
Glaucoma Typc,Consistcnt "With family's Type and other comments. 
GIST 
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1e <.ore .. 
Pressure Score 
Disc Score .... 
GIST SCORE. 
AppendixD Risk Factor Survey 
Glaucoma Inheritance Study GIST G /Registry Bleed 
Please c9mplete the following information to the best of your ability. If you do not know the answer please 
leave the question blank. 
'I oday's Date ...... i ...... ./. . Tune 
Surnrune ................................ . 
MaidllllName ................................ . GP ........................... . 
first·Namc. • .. . .. . .. .... . . ........... . Ophtlmlmologist ...................... . 
Address ........................................ . Date of Birth..... I ... .I . 
.. . Age ......................... . 
....... Post Code ..... 
Phone ............. . 
Do you have glaucoma'/ ........... . 
When was the date of DiaguosLq? ...... Your age at Diagnosis'! 
The highe~1 eye pressure 1fknowu?....... .. .. ..... 
Fathers side'? Yes/No 
Do you have a family history of glaucoma? Yesrl\'o Mothers side? YesrNo 
Number affected 
Please name your Glaucoma Medications ..... .,, ................ . 
!lave you ever had eye surgery or laser treatments for glaucoma? . .... ...... . .... ........... ........... ... . . ........ . 
What and \\-11e11?................ . .......... . . ....... . ................ . 
Do you have any other eye problems?... . . . . .. .. . . . . . . .. . . .. .. .. .. . . . . . . . . .. .. . . . .. . . .. .. .. . . 
Have you had any other eye surgery'! (What and When)...... .................. ............ . ........................ . 
or injury to your eyes? ...... .. 
..... ................................................... .. .. 
Are you on any general medications? 
Please name them if possible:. . .. . . . ................ . 
Do you have high blood pres~ure? 
Do you smoke? Yes/No 
Do you have diabetes? Yes/No 
Have you ever had a bloo~ tran~fusion? Yes/No Why? 
Have you ever had a heart attack, stroke or any other disease with hardening of tl1e arteries? 
Do you get cold hand~ or feet? Ye1J'No 
llave you had any thyroid flloblems? 
no yon suffer frnm migraine henduches'I Yes/Ne• 
Have you ever been on Cortisone or steroid medication? 
(cortisone eyedrops, nasal spray, s1eroid asthma ~pray, 
cortisone skin creams, steroid· injections or sterotd tablets) 
Yes/No 
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Yes/No 
AppendixE Protocol for Calculation of GIST Score 
INTRAOCULAR PRESSURE (IOP) 
Score 1 point if -
IOP is 22 mm.Hg or higher in either eye at time of examination or noted by a reliable 
third party prior to treatment. 
An additional point if -
IOP is 28 mmHg or higher in either eye at time of examination or noted by a reliable 
third party prior to treatment 
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OPTIC DISC ANALYSIS 
Scor~ APSA - appearance precludes satisfactory assessment if the appearance of the 
optic nerve head is sufficiently abnormal or has, or has had, a condition which makes 
exclusion of glaucoma impossible. No raw score is altered.Score. 
0 point - if the appearance of optic discs is normal or consistent with normal variation 
and not consistent with glaucoma.Score. 
1 point - if either or both optic nerve heads are unlikely to be normal and the 
app~arances are likely to be result from glaucoma, as characterised by one or two of the 
following: 
• A focal notch in the neuroreti.nal rim which does not extend to the margin 
• 'Drance'-type haemorrhages 
• A nerve fibre layer defect of at least two vein widths within one disc diameter of the 
disc margin 
• A cup disc ratio (CDR) of 0. 7 or greater, or 0.2 difference between the two eyes 
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Score 2 points - if the appearance of either or both the optic discs are not normal and 
the findings are considered to be highly likely to result from glaucoma, as characterised 
by one or more of the following: 
• An acquired pit of the optic nerve 
• A notch in the neuroretinal rim extending to the margin 
• A CDR of 0.8 or greater, or more than 0.2 difference between the two eyes 
• 'Drance'-type haemorrhages 
• Nerve fibre layer defect 
An Additional point - if the pathological appearance of the disc is considered highly 
typical of the phenotype. Findings include: 
• Gross posterior bowing of the lamina 
• Undermining of the neuroretinal rim (bean pot' cupping) 
• CDR of 0.9 or greater 
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VISUAL FIELDS 
Test results are assessed for reliability and defects with the following criteria: 
Fixation losses 
<20% losses 0 
>20% losses 1 
False positive errors 
<33% 0 
>33% 1 
False negative errors 
<33% 0 
>33% 1 
Short-term fluctuations (dB) 
<4 0 
4-6 
>6 
1 
2 
A field is considered reliable if it has a rating of 0 or 1. All fields with a rating of 2 or 
more are repeated where possible, as are tests with obvious artefacts or grossly abnormal 
intra-test reliability criteria. 
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The visual field is then classified based upon the pattern deviation plot as follows: 
A - N onnal field. Reliable field test where all points lie within the age-corrected normal 
values on the pattern deviation plot. 
B - Not significant for glaucoma. Reliable field test with minor depression at one or two 
points not considered significant for glaucoma on the pattern deviation plot, or defects 
of known or unknown cause not consistent with glaucoma. This is done by comparison 
with given values on the Humphrey Visual Field Analyser threshold 24-2 test total 
deviation plot for the miillmum amount of depression that varies with location (Figure 
IV.8). 
C - Significant and consistent with glaucoma. Reliable field test with three or more 
adjacent or clustered points within a hemifield or within the nasal field with significantly 
reduced thresholds and a pattern deviation plot consistent with glaucoma. 
D - Markedly degraded and highly consistent with glaucoma. Due to extensive field loss, 
reliability score may be 2 or more. 
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Category A and B have raw score of 0. 
Category C and D score 1. 
In any of the three parameters, an additional point may be awarded for a feature highly 
consistent with and typical of the pedigree pattern. However, only one additional point is 
ap.owed per individual, giving a maximum possible raw score of 5 and maximum GIST 
score of one (Coote 1996). 
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